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Abstract 
 
Renal Specific RNAi Delivery by Fibrillar Nanoparticle Excipients 
By 
Sam Wong 
 
Advisor: Yujia Xu and Michael McDevitt 
 
RNA interference (RNAi) is a powerful tool to manipulate the phenotype of an organism 
by silencing the expression of specific protein producing genes and is a highly promising 
platform for treating undruggable targets and disorders where small molecule drugs and 
antibodies falter. However, development of RNAi based therapies has faced major barriers 
including cellular and tissue-specific uptake of the Small Interfering RNA (siRNA). Utilizing 
nanoparticles as RNAi excipients, cellular uptake and gene silencing potency can be greatly 
improved. The research in Dr. McDevitt’s group with fibrillar single-walled carbon nanotubes 
(CNT) has shown that CNT are viable carriers for siRNA for gene silencing in vitro and in vivo. 
Radiolabeled biodistribution of ammonium functionalized CNT (fCNT) in mice show renal and 
hepatic uptake while having fast plasma clearance and excretion in the urine hours after 
injection. This unique pharmacokinetic profile has been termed Fibrillar Pharmacology due to 
the fibrillar nature of the nanoparticles that exhibit this unique behavior. 
The hypothesis of my thesis was that other high aspect fibrillar nanomaterials can also 
exhibit Fibrillar Pharmacology and are applicable as renal specific RNAi based therapeutic 
agents. During the course of my thesis research, I investigated the application of Vertically 
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Aligned carbon nanotubes (VACNT) and cellulose nanocrystals (CNC) that have been 
ammonium functionalized (fVACNT and fCNC, respectively) and physically characterized. In 
vivo murine biodistribution with radiolabeled conjugates of fVACNT and fCNC validated 
Fibrillar Pharmacology behavior and renal uptake. 
These two fibrillar nanoparticles present several characteristics that are desirable in the 
development of fibrillar RNAi delivery systems. VACNTs can be produced in large quantities 
with homogenous physical attributes. Also, with the increased dimensions of VACNTs, a greater 
number of siRNA bound each nanoparticle, as shown by titration with fluorescently labeled 
siRNA. The CNC studied here are a potentially cost effective and renewable source of fibrillar 
nanoparticles. Additionally, gene knockdown utilizing fCNC indicate this fibrillar nanoparticle 
as a robust platform for gene silencing in vivo and in vitro. 
Lastly, a possible therapeutic application of RNAi mediated via fibrillar nanoparticles 
was explored by targeting the renal glucose co-transporter Sodium dependent GLucose co-
Transporter 2 (SGLT2). SGLT2 has been focused on in the treatment of Diabetes Mellitus Type 
2 as a means of mitigating hyperglycemia in patients. While it still needs more extensive 
examination, the work here indicated that by combining RNAi with Fibrillar Pharmacology it is 
possible for renal specific silencing of SGLT2 mediated by fCNT leading to excretion of glucose 
and potentially reducing decreasing blood glucose levels. 
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Introduction 
 
RNA interference (RNAi) can be a powerful therapeutic tool for many disorders. By 
introducing Small Interfering RNA (siRNA) into cells the endogenous machinery can utilize the 
siRNA, target and degrade specific mRNA sequences thus “silencing” or “knocking down” 
protein translation. The stability of RNA, cellular and tissue-specific uptake are several hurdles 
that prevent potential RNAi based therapies from being approved for clinical. High aspect ratio 
nanoparticles such as carbon nanotubes (CNT) exhibit fast plasma clearance while taken up 
intracellularly in the kidneys in vivo, termed Fibrillar Pharmacology. Combining RNAi with 
Fibrillar Pharmacology the issues of tissue-specific delivery and cellular uptake can be 
surmounted. In this work, the use of fibrillar nanoparticles, such as single-walled carbon 
nanotubes (swCNT), vertically aligned carbon nanotubes (VACNT), and cellulose nanocrystals 
(CNC) as RNAi delivery platforms to specifically target the renal system is explored. This work 
will focus on overcoming the challenges of tissue-specific and cellular uptake of these fibrillar 
nanoparticles.  
As initial steps in developing a therapeutic agent, the nanoparticles are chemically 
functionalized, characterized and then as a proof of concept shown to silence gene expression in 
vitro and/or in vivo. As a potential clinical application of RNAi paired with Fibrillar 
Pharmacology, silencing of a glucose transporter, SGLT2, mediated by swCNT to potentially 
treating hyperglycemia is investigated. SGLT2 is expressed exclusively in the kidneys and its 
activity has been implicated in exacerbating hyperglycemia in T2DM patients. Inhibition of this 
transmembrane protein has led to glucosuria and decreasing blood glucose levels thus improving 
the major symptom of the T2DM.  
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RNAi and siRNA Background 
It was once widely believed that protein synthesis was a one-way path. Known as the 
Central Dogma of molecular biology (1), DNA was transcribed into mRNA which was then in 
turn translated into protein (Figure 1). In this model there was no way for protein or RNA to 
regulate or alter the expression of genes. Later, it was discovered that viral RNA can be 
converted into DNA by the viral enzyme Reverse Transcriptase by Howard Temin and David 
Baltimore (2-4). This led to the idea that the Central Dogma was not absolute and there could be 
other methods to alter gene expression. In their Nobel winning, Fire and Mello showed that in C. 
elegans exogenous double stranded RNA (dsRNA) introduced into a cell could alter the 
expression of specific genes (5). These RNA duplexes were later called Small Interfering RNA 
(siRNA) and led to the field of RNA Interference (RNAi) where the cell’s endogenous 
machinery is exploited to degrade specific mRNA sequences and in turn halt protein translation. 
This finding has transformed understanding of gene expression from a linear, unidirectional 
process to one that can be altered post transcriptionally. Later it was also discovered that proteins 
can directly change gene expression by methylation of DNA and by altering the accessible 
regions of chromatin for transcription, known as epigenetics. 
 
Figure 1: Central Dogma of Molecular Biology. Protein expression is a linear process where DNA encoding a 
gene is transcribed into RNA and then translated into protein. DNA can be replicated using itself as a template. 
However, RNA and proteins can affect gene expression. RNA through reverse transcriptase can be converted into 
DNA.  Image from https://byjus.com/biology/central-dogma/. 
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History and Mechanism of RNAi 
Using short RNA sequences Fire and Mello were able to “silence” gene expression in the 
nematodes C. elegans (5). In their work, the pair introduced single stranded sense, antisense 
RNA (ssRNA) or sense-antisense RNA duplexes into cells to alter protein expression of specific 
gene. The sense strand’s nucleotide sequence was homologous to the target mRNA while the 
antisense strand was complementary to the target. Single stranded RNA showed limited effect in 
gene silencing, possibly due to degradation of the RNA. On the other hand, double stranded 
RNA resulted in loss of function phenotypes or in some cases null mutants. Fire and Mello’s 
work showed how powerful double stranded RNA (dsRNA) could be in silencing gene 
expression. Moreover, gene silencing could be passed onto the progeny of the cells injected with 
the dsRNA when they divided displaying the persistent effects of gene silencing. The group also 
realized two major hindrances with RNAi that would continue to affect the field decades later. 
First, off-target silencing could lead to unwarranted side effects in unintentional silencing as a 
consequence of mRNA sequences of different genes having close homology and second, 
incomplete silencing of the target gene due to inefficiency of degrading targeted mRNA. 
At the time Fire and Mello did not know the molecular mechanism for gene silencing, but 
the field has advanced greatly since 1998. After introduction into a cell, the dsRNA is processed 
by DICER into short 21-23 base pair (bp) sequences (6-8). One strand of the dsRNA duplex, 
called the “guide” or antisense strand is loaded onto the RNA Induced Silencing Complex 
(RISC) (Figure 2). Its complement, the sense strand in the duplex also called the “passenger” 
strand, will ultimately be degraded (9-13). The guide strand is identified by its 3’-dinucleotide 
overhang and is complementary to the target mRNA, while the sense strand is homologous to the 
target.  
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Figure 2: Mechanism for RNA Interference (RNAi). Long double stranded RNA (dsRNA) is introduced into a 
cell and processed into ~21 nucleotide long duplex siRNA by Dicer. The guide strand of the duplex siRNA will be 
loaded onto RNA Induced Silencing Complex (RISC) while the passenger strand is degraded. RISC will search the 
cytosol for mRNA sequences complementary to the guide strand and after assembling with Argonaute (AGO) will 
either cleave, cause DNA methylation or translation inhibition of the target mRNA. Secondary siRNA are generated 
during the process of cleaving the target mRNA leading to amplification of RNAi. Image from Limera. 2017. 
Frontiers in Plant Science. 
RISC is composed of a wide array of proteins and RNA working in concert. One 
important component of RISC is the protein Argonaute 2 (Ago2), formerly called “Slicer”, 
which positions the guide strand within RISC and contains a domain with RNase H activity. 
With the guide strand in place, RISC will survey the cytosol for mRNA sequences 
complementary to the guide strand based solely on hybridization. Nucleotides 2-8 from the 5’-
end of the guide strand called the “seed region” for their compulsory Watson-Crick base pairing 
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ability with potential mRNA, partners while bases 10-11 help to orient the scissile phosphate 
group for Ago2 to cleave (14-17). 
The target mRNA will be cut by Ago2 into 21-23 base fragments preventing further 
protein synthesis using the cleaved mRNA molecule as a template (18). Subsequently, the RISC 
complex can continue patrolling the cytosol in search of complementary mRNA sequences until 
either the complementary mRNA pool is depleted or the loaded guide strand is released from 
RISC. Therefore, the stability and residency time of the guide strand in the RISC complex is an 
important factor in how potent the silencing of gene expression.  
 
Advantages of RNAi as a Drug 
Altering the protein expression of an organism is a powerful method of changing the 
phenotype of the organism. As all proteins must be translated from mRNA encoding them, 
siRNA targeting the mRNA sequences and directing it for degradation would prevent the 
synthesis the of encoded products. Silencing gene expression was a highly effective tool in 
studying and determining gene function in C. elegans allowing groups to map genes with protein 
function (5). Almost immediately after the discovery of RNAi in C. elegans it was surmised that 
RNAi could be exploited in the treatment of a wide array of diseases and disorders including 
viral infections (HIV and Hepatitis), cancer, neurodegenerative and autoimmune disorders (19-
33). The field of RNAi expanded rapidly in the late 1990’s and early 2000’s with the proteins 
associated and silencing mechanism of RNAi elucidated. Then in 2006 Fire and Mello won the 
Nobel Prize in Physiology or Medicine for their seminal work with RNAi, further popularizing 
RNAi in biology and its potential therapeutic application. 
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RNAi therapeutics provide several critical advantages not seen with small molecule 
therapeutics or biologics such as antibodies (Table 1). Because of the requirement of 
hybridization of target mRNA with the guide strand’s seed region, RNAi can theoretically target 
any protein encoding gene within an organism’s genome with great specificity. Additionally, this 
could lead to fewer off-target effects compared to small molecule drugs which can bind to 
numerous enzymes or receptors that share similar binding pockets or from the same protein 
family. Finally, introduction of just a few thousand molecules of siRNA could lead to 
amplification of gene silencing due to production of secondary siRNAs from cleaved target 
mRNA (34, 35). 
Table 1: Advantages and challenges to developing RNAi based therapeutics. 
Advantages Challenges 
• Can target virtually any gene including 
“undruggable” targets 
• Off-target silencing can produce unwanted 
side effects 
• Highly specific guide strand sequence can 
lead to fewer off-target effects 
• Instability of RNA in serum and intracellular 
environments 
• Utilizes endogenous cellular machinery to 
silence gene expression 
• Charged RNA backbone prevents diffusion 
across cell membrane 
• Many chemistries to modify RNA backbone 
to prevent degradation and enhance silencing 
• Lack of tissue-specific uptake 
• Production of secondary siRNAs lead to 
amplification and prolonged silencing 
 
 
Many commercially available drugs are small molecules or biologics that can only target 
receptors or enzymes, limiting the total potential targets in the proteome. This presents two 
issues first, only catalytically active or proteins on the surface of the plasma membrane can be 
targeted and second, discrimination between the target receptor and similar binding sites that are 
not meant to be targeted is not possible leading to off-target effects (36, 37). The small molecules 
drugs can only bind into the catalytically active site or an allosteric site, while biologics such as 
antibodies can only bind surface exposed epitopes. Additionally, identifying catalytic sites and 
epitopes that can be targeted for inhibition can be an arduous task requiring prior structural 
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knowledge of the target protein, computational assessment and chemical synthesis rounds of 
selection to identify a lead drug. Unexpected binding to off-target proteins with a similarly 
folded epitope can potentially cause unwarranted side effects. Finally, these drugs can only target 
and inhibit proteins that have been synthesized, but not able to prevent the buildup of faulty or 
misfolded proteins that could lead to disease.  
RNAi based drugs can ameliorate many of these issues and vastly increase the number of 
possible targetable genes to theoretically all genes that will be translated (37-40). First, 
knowledge of the structure for the protein responsible for a disease is not required, only 
knowledge of the gene’s mRNA transcript is needed. Synthesis of all proteins is preceded by the 
transcription of mRNA. As all mRNA molecules share similar composition: a negatively charged 
sugar phosphate backbone, a 5’-7-methylguanosine cap sequence and 3’-polyadenylated tail; the 
defining characteristic of an individual mRNA molecule is the sequence of nucleotide bases 
which encodes its protein product. Hybridization of the seed region of the guide strand creates a 
highly specific requirement for correct pairing with an mRNA molecule prior to cleavage and 
leads to fewer off-target cleavage of mRNA with similar sequences. 
Studies in antisense strand sequence optimization and preferential selection improve 
robustness of gene silencing. Work by Elbashir and others’ with synthetic dsRNA helped to 
optimize the length to be ~21 nucleotides (41) while others have found that duplex RNA 
processed by DICER are more efficient at gene knockdown, leading to developments in 
optimizing oligo length of double stranded DICER substrate duplexes RNA (dsiRNA) (42, 43). 
Additionally, selection of the guide strand selection elucidated several general guidelines such as 
the “asymmetry rule”: the strand with two 3’-nucleotide overhangs is preferentially loaded onto 
RISC for target recognition (42, 44). Computational studies with genomes of C. elegans and 
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other organisms including humans have generated non-degenerate siRNA libraries leading to 
greater specificity and fewer off-target silencing and have become readily available (45-48).  
Finally, neural networks utilizing large data sets can learn and predict siRNA for the knockdown 
of desired genes (47). 
A fascinating outcome in work with C. elegans, when target mRNA are cleaved by a 
guide strand loaded RISC is the formation of secondary siRNAs (34, 35). This cleavage product 
can be differentiated from the progenitor siRNA based on its 5’-end di- or triphosphates, whereas 
the precursor siRNA processed by DICER contains a single 5’-end phosphate (34, 35). The 
secondary siRNA can likewise be processed, loaded onto RISC and used to target mRNA for 
destruction. Formation of secondary siRNAs and the increased population of RISC complexes 
loaded with guide strands greatly amplify and prolong the silencing effect even if only a handful 
of siRNA is introduced into a cell initially. Those initial siRNA molecules introduced to a cell 
can propagate into many copies and be passed onto daughter cells as seen by Fire and Mello 
allowing gene silencing to continue in the progeny cells (5).  
 
Hurdles to RNAi Therapy and Advancements 
Since RNAi’s discovery gene silencing has been suggested as a potential therapy for 
many diseases however, development has stymied and there is currently only one Food and Drug 
Administration (FDA) approved siRNA based therapeutic, Patisiran (trade name Onpattro) 
developed by Alnylam Pharmaceuticals for treating hereditary transthyretin-mediated 
amyloidosis (49, 50). Because RNAi relies on the uptake of siRNA for processing and gene 
silencing, stability of the siRNA in both the extracellular and intracellular milieus, tissue-specific 
delivery and crossing the plasma membrane are several of the most difficult obstacles for siRNA 
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progress. Furthermore, the potential of off-target silencing and variable silencing efficiency 
caused apprehensions over using RNAi in humans. A great body of work has been performed by 
many groups to improve RNAi silencing efficiency and efficacy (51, 52). 
RNA is a relatively unstable molecule. Both the extracellular and intracellular 
environments where endonucleases, exonucleases and RNases are present and can degrade the 
molecules. SiRNA by itself is highly susceptible to degradation with half-lives of minutes to 
hours in serum (53). SiRNA degradation by RNase before it can be processed by DICER and 
loaded onto RISC severely impairs gene silencing. Additionally, under basic conditions the 2’-
hydroxyl group on the ribose sugar can act as a nucleophile to attack the phosphate group linking 
successive ribose sugars in the RNA backbone. A nucleophilic attack by the 2’-hydroxyl group 
leads to cleavage of the sugar phosphate backbone into fragments.  
To mitigate the issue of siRNA’s innate instability and improve its half-life, extensive 
studies in chemical modifications of the ribose sugar and the siRNA’s backbone have been made 
(54-62). As mentioned previously, the 2’-hydroxyl group present in the ribose ring of RNA is 
capable of autolysis of the sugar phosphate backbone. To prevent this several groups have 
replaced the 2’-hydroxyl group with poor nucleophiles such as 2’-fluoro, 2’-O-methyl, 2’-
halogen or 2’-deoxy groups (54, 55, 63-65). These modified sugar bases have shown improved 
stability of the siRNA and in some cases increase the stability to 90 hours using Locked Nucleic 
Acids. As an additional benefit these modifications do not impede gene silencing (54). 
Cellular uptake due to the negatively charged sugar phosphate backbone of RNA presents 
an additional hindrance to gene silencing. The negatively charge sugar backbone prevents siRNA 
from passively diffusing through the plasma membrane, requiring active transport of the siRNA 
across the membrane or the siRNA to be delivered by a delivery vehicle. In most cases 
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endocytosis mediates the uptake of siRNA (69). Chemical modifications of the sugar phosphate 
backbone from anionic diphosphate bonds to phosphorothioate or boranophosphate linkages can 
diminish the net negative charge of the oligo. 
As an example of a chemically modified nucleotide and sugar phosphates groups to 
improve stability, the first FDA approved siRNA-based therapy Patisiran from Alnylam 
Pharmaceuticals improve its serum half-life and binding with target mRNA (Figure 3). The 
ribose ring has been modified in the 1’-hydroxyl position with boron while the 2’-hydroxyl has 
been changed to deoxy- on the 3’-terminal thymidines (highlighted in red in Figure 3) while 
others contain 2’-O-methoxy groups in place of the hydroxyl (highlighted in blue). 
 
Figure 3: Chemical modifications of Patisiran. Patisiran from Alnylam Pharmaceuticals consists of a double 
stranded siRNA containing modified nucleotide bases to increase stability and potency. All 1’-hydroxyl groups on 
the ribose sugars were substituted with a boron atom while the 3’-thymidines were substituted the 2’-hydroxyl 
groups with hydrogen (Red bases). Additionally, specific bases have also been O-methoxy ribose rings (Blue bases). 
Patisiran silences the expression of Transthyretin (TTR) to treat Amyloidosis Hereditary Transthyretin (hATTR). 
Image from Al Shaer et al. Pharmaceuticals 2018. 
Another example, Inclisiran from Alnylam Pharmaceuticals decreases low-density 
lipoprotein (LDL) cholesterol by silencing the expression of PCSK9 in the liver.  In a clinical 
study patients’ PCSK9 levels decreased by ~40% and LDL cholesterol by ~30% for up to 240 
days with a single 200mg dose (66-68). Another treatment arm in the same trial received a 
second dose 90 days after the first had PCSK9 decreases by ~60% at 240 days after the initial 
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dose. The study showed the effective RNAi silencing for 8 months with a single dose of the 
drug.  
Work in the field of RNA modifications for RNAi applications has led to the formation 
of “Anti Sense Oligonucleotides” (ASO). ASO are single stranded RNA, usually with modified 
sugar phosphate backbones or DNA nucleotide bases that use a different mechanism to mediate 
RNAi. Rather than introducing a duplexed siRNA, recognition and processing by DICER and 
recruitment into RISC, ASO are introduced as single stranded RNA, can independently bind to 
their mRNA target forming an RNA-RNA duplex (70). RNA duplexes can block translation 
followed by degradation by RNase H or modulate mRNA splicing. ASO technologies has led to 
the development of two FDA approved ASO therapies, Fomivirsen for treating cytomegalovirus 
retinitis and Mipomersen for familial hypercholesterolemia (71, 72).  
Finally, one of the greatest dilemma limiting RNAi drugs that must be addressed is the 
lack of tissue-specific uptake of siRNA. Naked siRNA is primarily taken up in the liver limiting 
the scope of potential gene targets involved to hepatic diseases (69). Easily accessible tissues 
such as the skin and corneas of the eyes also provide facile administration routes, but again limit 
prospective therapy applications (51, 52). Delivery of RNAi to other tissues is desirable to widen 
the span of potential disorders that RNAi can be applied to. Utilization of delivery vehicles can 
alter the pharmacokinetic profile of the siRNA drug or improve tissue uptake. Alnylam 
Pharmaceuticals’ Patisiran is administered as a lipid nanoparticle formulation to increase its 
stability and improve hepatic uptake.  
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Patisiran, the First FDA Approved siRNA Based Drug 
Utilizing highly target specific siRNA gave RNAi the potential to target nearly any 
protein producing gene in an organism’s genome, including many that were considered 
undruggable. Additionally, the requirement of complementarity to the guide strand before RISC 
can degrade the mRNA molecule decreases the number of possible off-target silencing. 
Furthermore, after the degradation of complementary mRNA sequences, secondary siRNA are 
generated to not only amplify the effect of gene silencing but it would also increase the pool of 
siRNA molecules in a cell allowing the silencing effect to last for longer periods of time. 
As promising as RNAi therapeutics appeared to be when it was first discovered, only a 
single drug has been approved by the US Food and Drug Administration (FDA). Patisiran 
developed by Alnylam Pharmaceuticals was the first siRNA-based drug to be approved by the 
FDA in August 2018, twenty years after Fire and Mello first published their work. Patisiran has 
been approved to treat Hereditary Transthyretin-mediated Amyloidosis (hATTR). 
RNAi therapeutics can preemptively prevent the buildup of defective proteins, thus 
slowing down or stopping disease progression. Patisiran’s purpose is to prevent the expression of 
the transthyretin gene (TTR). TTR encodes a 127 amino acid carrier for retinol binding protein 
and transports vitamin A in the body. It is expressed primarily in the liver and the brain but can 
be secreted into the extracellular fluids. Mutations in the TTR gene can lead to the autosomal 
dominant disorder Hereditary Transthyretin Amyloidosis (hATTR) where TTR protein produced 
is misfolded and forms amyloid fibrils (73-75). Secretion of the amyloid fibrils into the 
extracellular fluids cause accumulation of the amyloid fibrils and lead to malfunction in nearby 
organs. Notably, amyloid aggregation in the peripheral nerves will lead to neuropathy, reduced 
sensorimotor function, decreased ambulation and negatively impacted quality of life while 
13 
 
buildup in the heart can lead to heart failure, arrhythmias or orthostatic hypotension (76). Those 
diagnosed with hATTR are expected to live 2-15 years after the onset of neuropathy and even 
less time for those experiencing cardiomyopathy. 
 Alnylam Pharmaceuticals has produced the first siRNA-based drug (Patisiran) to treat 
hATTR (49). Patisiran is a lipid nanoparticle (LNP) formulation of double stranded RNA 
sequence containing several modified nucleotides (Figure 3). The LNP formulation is to aid the 
stability and uptake of the drug into the liver where the cell’s RNAi machinery will process the 
siRNA and use it to degrade TTR mRNA. In a Phase 3 clinical trial for Patisiran, patients were 
given intravenous injections of the drug once every 3-weeks for an 18-month period. During the 
trial, patients that received Patisiran showed nearly 80% lower levels of serum TTR compared to 
the placebo group (Figure 4), additionally participants reported improvements quality of life 
assessments by questionnaires.  
Together this data shows that siRNA-based therapeutics has great potential in treatments. 
Many of the obstacles that RNAi based drugs face were overcome by clever formulation of the 
drug to increase stability and uptake into the liver. Patisiran’s Phase 3 trial showed that the 
siRNA drug was effective at lowering serum TTR and sustained the decrease over the 3-week 
intervals between doses (76). With the success of Patisiran other groups and companies have 
heightened their development of RNAi based therapeutics. One of the major challenges that 
remain is tissue-specific targeting.  
Naked siRNA and lipid nanoparticle formulations like Patisiran are primarily taken up by 
the liver, limiting the possible organs that can benefit from RNAi therapeutics. Other delivery 
systems may provide expanded tissue-specific targeting. Water soluble fibrillar nanoparticles, 
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which are taken up primarily in the kidneys, open a new field of potential disorders and diseases 
that can be treated by RNAi. 
 
Figure 4: Summary of a Patisiran Phase 3 clinical trial. Patisiran safely and efficiently treats hATTR. hATTR 
patients were given 1 dose of either placebo (n = 77) or Patisiran (n = 148) every three weeks for 18-months. 
Throughout the trial patients who received Patisiran showed ~80% less serum TTR (Panel A). Patients were given 
questionnaires to assess their neurological impairment and quality of life (Panel B, C and D). In both questionnaires 
Patisiran participants scored less neurological impairment and improved quality of life (lower values indicate 
improved condition). Image from Gonzalez-Duarte NEJM 2018.  
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Fibrillar Pharmacology 
 Many of the issues of RNAi therapeutics have been assuaged but organ/tissue-specific 
uptake of RNAi remains a major roadblock. Naked siRNA and duplex RNA that have been 
chemically modified are primarily taken up by the liver and are quickly excreted through the 
kidneys (77, 78). Most of the current RNAi drugs in development focus on targeting the liver, 
eyes or skin where application or uptake of the drug is straightforward (48). By incorporating 
different chemical modifications or delivery methods, uptake and efficacy of RNAi can be 
improved and even alter tissue uptake of the drug. Dr. McDevitt’s group at Memorial Sloan 
Kettering Cancer Center has studied fibrillar nanoparticles as delivery platforms for renal siRNA 
delivery. 
Fibrillar nanoparticles such as carbon nanotubes and cellulose nanocrystals possess 
several unique physical properties that make them desirable for many applications. Carbon 
nanotubes (CNT) were first described by Sumio Iijima as long “needle-like tubes” with 
diameters in the nanometer range and high aspect ratios (79). Since their discovery CNTs have 
been lauded as a superb material for a wide array of applications due to their coveted physical 
(strength and rigidity) and electronic properties (high electrical and thermal conductivity) (80-
85). Many medical applications and drug delivery systems have been proposed using CNTs (77, 
80, 86, 87).  
Our group and others have explored the application of fibrillar nanoparticles, such as 
single-walled carbon nanotubes, to be utilized as excipients in drug delivery. One major issue 
that must first be overcome for applying the CNT to biological systems is the hydrophobic nature 
of CNT causing them to aggregate. By chemically functionalizing pristine CNT they can be 
made water soluble and readily dispersed. Previous members of the McDevitt group chemically 
16 
 
functionalized single-walled CNTs (swCNT) with ammonium groups allowing their surfaces 
have a net positive charge. Some of the ammonium groups were then further modified by 
covalently attaching ligands (either an antibody or an oligonucleotide sequence) (88, 89). These 
ligands help the water-soluble CNT target an epitope directly on the surface of a cell. In the case 
of the oligo sequence, an antibody appended with a complementary oligo sequence to pre-target 
a desired epitope and then dosing with the CNT-oligo to allow the oligos to hybridize at the site 
desired for “oligonucleotide-directed self-assembly in vivo in diagnostic and therapeutic 
applications” (88). In these two examples multimodal water-soluble CNT could target and 
deliver a therapeutic or diagnostic passenger to a desired target tissue via a targeting moiety (i.e. 
an antibody conjugated to the CNT). Without these moieties CNTs experience quick blood 
clearance from the body but can also be passively transported into the cells of the kidneys. 
Due to their fibrillar shape and high aspect ratios water soluble single-walled carbon 
nanotubes can be filtered by the kidneys and collect in the bladder, while a fraction of the 
injected nanoparticle was taken up by the kidneys and liver (88, 90-92). This phenomenon has 
been called “Fibrillar Pharmacology” (78, 90). In this work, the possibility of utilizing several 
fibrillar nanoparticles in drug delivery to the kidneys and liver is examined. 
 The kidneys play a key role in filtering out waste while retaining important metabolites. 
The glomeruli present in the kidneys acts as a physical barrier to prevent large macromolecules 
from continuing down the path to be excreted in urine (93). The glomerulus contains pores as 
well as slits that can expand to accommodate some larger molecules but globular molecules 
larger than >50kDa are not expected to pass through the glomerulus. It is thought that the pores 
of the glomerulus range from 45-100 Angstroms (4.5-10nm) (Figure 5) (94). Small molecules 
such as glucose, urea and ions can pass through the glomerulus into the Proximal Convoluted 
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Tubules (PCT) where a variety of transporters will reabsorb crucial metabolites (glucose, small 
peptides, bicarbonate, sodium, and potassium) while allowing others to pass through and be 
collected in the bladder for excretion. Besides the size restriction of the glomerulus anionic 
molecules are also restricted from passage (93, 94). 
 
Figure 5: Filtration of carbon nanotubes through glomerulus of nephron. Due to their high aspect ratio and 
fibrillar nature CNTs can align with the blood flow allowing them to pass through the glomerulus (diameter ranging 
from 5-60nm), into the Bowman’s capsule and ultimately are excreted. Image from Kostarelos Nat Mat 2010. 
 
 Surprisingly, Ruggiero et al. found that mice treated with functionalized swCNT 
decorated with several fluorophores and radiolabeled with the isotope Yttrium-86 (SWCNT-
[([
86
Y]DOTA)](AF488)(AF680)) could quickly clear blood circulation through the kidneys and 
nearly 65% was excreted in the urine (90). Dynamic Positron Emission Tomography (PET) time 
lapse images showed one-minute post injection the radiolabeled constructs began appearing in 
the kidneys and within 5 minutes they started to clear from the renal system and collect in the 
bladder along with the urine (Figure 6a and b). Urine collected from mice showed that the urine 
contained the same constructs that was injected based on radio and fluorescence HPLC (Figure 
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6f and g). In addition to the fast blood clearance of the nanotubes, PET imaging showed 
increased radioactivity in the kidneys, liver and spleen compared to the blood suggesting specific 
uptake of the radiolabeled nanotubes in those organs.  
 
Figure 6: Renal clearance of functionalized single-walled carbon nanotubes (swCNT). fCNT show rapid blood 
clearance not mediated by several common transporters. Dynamic PET imaging of SWCNT [
86
Y]DOTA-AF488-
AF680 in mice showing blood clearance with uptake of the radiolabeled nanoparticle in the kidneys (Panel A) and 
accumulation in the bladder (Panel B) as 3 minutes post injection. Inhibition of several common transporters present 
in the kidneys does not prevent clearance of the swCNT suggesting that the swCNT are not actively carried across 
the glomerulus (Panels C, D and E). Radio HPLC of SWCNT [
86
Y]DOTA-AF488-AF680 collected in the urine of 
mice showing that they are excreted intact. Image from Ruggiero PNAS 2010. 
 
Transport of fCNT across the glomerulus is a passive process. Inhibition of several active 
transporters: cimetidine for inhibiting organic cation transporter (OCT), probenecid for organic 
anion transporter (OCT) and gentamicin for megalin transporter systems responsible for 
secretion of molecules did not abrogate the excretion of the fCNT (Figure 6c, d and e). This 
suggested that fCNT transport across the glomerulus was not mediated by protein transporters 
but was instead a passive procedure. Considering that the fCNTs were 100-300nm with 
molecular weights between the range 350-500kDa it was not expected that these nanoparticles 
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would be able to pass through the glomerular filtration system; they were significantly larger 
than the proposed cut off size that could be filtered. 
 Not only were the fCNT constructs excreted through the kidneys, but 15% of the 
radiolabeled nanotubes injected were also imported into cells lining the Proximal Convoluted 
Tubules (PCT) cells. Near IR images showed increasing accumulation of the nanotubes over a 
period of 24 hours with the greatest intensity at 5 minutes post injection (Figure 7a). 
Immunofluorescence (IF) images likewise showed fluorescence from the (SWCNT-
DOTA)(AF488)(AF680) localizing in the cytoplasm of the cells (Figure 7b and c). This 
phenomenon was previously seen before by other groups, but no model was proposed to explain 
this event (95). Ruggiero’s model proposed that due to the high flow rates of the kidney filtration 
system, the nanotubes’ high aspect ratios and rigidity allowed the nanotubes to align with the 
flow of the fluids to pass through the glomerulus. Potentially other fibrillar nanoparticles that fit 
the model would behave similarly to their presented work. 
 
Figure 7: Images of [
86
Y]DOTA-AF488-AF680 uptake in the kidneys of mice over 24-hour period. Near IR 
images of mouse kidneys showing uptake of swCNT [
86
Y]DOTA-AF488-AF680 (Panel A) showing uptake and 
retention of the radiolabeled CNT construct in the kidneys. Immunofluorescence imaging of the kidney cortex 
(Panel B). Immunohistochemistry (IHC) images of kidney cortex (Panel C). White arrows indicate the Proximal 
Tubule brush border; red arrow signifies the glomerulus; yellow arrow indicates cytoplasm of a cell and magenta 
arrow points to cell nuclei. Image from Ruggiero PNAS 2010. 
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 Combining Fibrillar Pharmacology with RNAi, Alidori et al. showed that functionalized 
carbon nanotubes carrying siRNA could silence gene expression in the kidneys. Ammonium 
functionalized carbon nanotubes bind with oligonucleotide duplex sequences primarily through 
electrostatic interactions with nanomolar affinity and a ratio of ~2 siRNA : 1 fCNT (Figure 8) 
(91, 96, 97). In vitro studies demonstrated fCNT carrying siRNA specific for Enhanced Green 
Fluorescent Protein (eGFP) decrease its protein expression in HeLa cells (Figure 9).  
 
Figure 8: Functionalized carbon nanotube (fCNT) with a siRNA bound. Pristine single-walled carbon nanotubes 
were chemically functionalized to present ammonium groups on their surface. The oligonucleotide’s negatively 
charged backbone can bind with the fCNT through electrostatic interactions with the ammonium group and pi 
interactions between the nucleotide and the surface of the CNT. In the image a fluorophore was also conjugated to 
the 5-end of oligonucleotide. Image from Alidori STM 2016. 
 
 
Figure 9: Silencing of eGFP expression in vitro. Fluorescence images of cells treated with either siRNA alone, 
Lipofectamine with specific siRNA (Lf/sieGFP) positive control or fCNT with specific siRNA (fCNT/sieGFP) and 
quantification of fluorescence (Panel A). The cells treated with Lf/sieGFP or fCNT/sieGFP show decreased eGFP 
expression 24 and 60 hours post treatment. Flowcytometry of cells showing decreased eGFP fluorescence in cells 
treated with Lf/sieGFP or fCNT/sieGFP compared to PBS and sieGFP only controls (Panel B). Western blot of 
eGFP protein in cells showing specific gene silencing with fCNT/sieGFP and Lf/sieGFP and quantification (Panels 
C and D). Image from Alidori STM 2016. 
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Figure 10: In vivo silencing in transgenic mice. Transgenic mice expressing eGFP were administered either PBS, 
fCNT with eGFP siRNA (fCNT/siEGFP), eGFP siRNA alone (sieGFP alone) or fCNT with a negative control 
siRNA (fCNT/siScram). Images of kidney cortex showing decreased eGFP expression in mice treated with 
fCNT/siEGFP and a marginal decrease when treated with siEGFP alone (Panel A). Quantification of total eGFP 
fluorescence and nuclei stained with DAPI and eGFP staining area normalized to nuclei staining (Panel B and C). 
Western blot analysis mouse kidneys after treatment showing decreased expression of eGFP in mice treated with 
fCNT/siEGFP (Panel D). fCNT/siEGFP treated kidneys show significantly less eGFP fluorescence compared to 
controls. Image from Alidori STM 2016. 
 
To further strengthen the argument that fibrillar nanoparticles can effectively deliver 
RNA in vivo experiments with transgenic mice expressing eGFP were treated with fCNT. 
Transgenic mice expressing eGFP showed significantly less eGFP expression by 
Immunohistochemistry (IHC) and Western blot staining compared to mice treated with either 
siRNA alone or fCNT/scramble siRNA sequence (Figure 10). Whereas siRNA by itself (labeled 
sieGFP in the figure) showed no gene knockdown, most likely due to degradation of the siRNA 
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in the media, the groups treated with sieGFP delivered by either Lipofectamine (Lf) or fCNT 
showed significant loss of fluorescent protein expression. The in vivo and in vitro results show 
that the sieGFP is delivered into the cells intact for the RNAi machinery to process, overcoming 
the issue of limited stability of siRNA. 
Additionally, PET/CT imaging of cynomolgus monkey showed similar pharmacokinetic 
profiles as mice giving credence to how fCNT performance can translate into a nonhuman 
primate system (92). Finally, Alidori introduced the idea that the fCNT excipients carrying 
siRNA could be used in treating damage caused by Acute Kidney Injury (AKI) by silencing 
Meprin-1B (Mep1b) and p53 in mice as a prophylactic treatment regime. 
Patients receiving chemotherapy can experience AKI caused by uptake of cytotoxic 
cisplatin in the kidneys by the copper transporter Ctr1. Damage to the renal cells leads to the 
increased expression of the AKI markers p53 and Mep1b which in turn causes the cells to begin 
the process of apoptosis and decreased kidney function (98). By preventing the expression of 
both p53 and Mep1b by simultaneous fCNT/siRNA delivery, Alidori demonstrated decreased 
expression of the AKI markers in mice treated with fCNT/siRNA (Figure 11). Additionally, 
prophylactic treatment with fCNT/siRNA followed by injury induced by cisplatin showed 
increased survival rates (Figure 11b) decreased AKI marker expression (Figure 11c) and 
decreased fibrosis in renal tissue (Figure 11d). 
Together these works establish ammonium functionalized carbon nanotubes as a robust 
RNAi delivery system specifically for the kidneys. Their fast plasma clearance can reduce the 
toxicity and tissue-specific uptake in the kidneys and liver (91, 92, 99) as well as passive kidney 
and liver targeting, and the fCNT/siRNA complexes can be endocytosed into cells where their 
cargoes are be released. The ability to attach ligands through covalent or noncovalent means on 
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the surface of fCNT can illustrate the multimodal functionalities for therapeutic and diagnostic 
applications the fCNT can employ.  
 
Figure 11: Prophylactic treatment with fCNT/siRNA protects against Acute Kidney Injury (AKI). Mice 
prophylactically treated with fCNT/siRNA targeting Mep1b and Trp53 showed significantly less kidney damage 
than controls. Mice were injected for 5 consecutive days (Panel A blue arrows) and on day 0 given cisplatin. The 
serum (green arrows), weights (black arrows) and histology (purple arrows) were taken. Survival curves of mice 
treated with either siRNA alone, fCNT with a scramble sequence, fCNT with both Mep1b and Trp53 siRNA in 
combination or fCNT and only one of the siRNA (Panel B). Scoring of kidney injury (Panel C), lower values means 
less damage. Immunohistochemistry staining of kidney sections to visualize morphology and cisplatin induced 
kidney damage (Panel D). Mice given fCNT with a combination of siRNA targeting Mep1b and Trp53 showed 
significantly longer survival than animals given only one siRNA or controls. Image from Alidori STM 2016. 
 
Application of RNAi in Diabetes Mellitus Type 2 
 In the last chapter of this thesis, we will delve into the application of RNAi 
delivered by single-walled carbon nanotubes in silencing the renal sugar transporter Sodium-
dependent GLucose co-transporter 2 (SGLT2) for treating Type 2 Diabetes Mellitus (T2DM). Of 
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the patients diagnosed with diabetes ~90% of patients will have Type 2 while ~10% will be 
diagnosed with Type 1, pregnant women can experience gestational diabetes and there are other 
less prevalent forms. Diabetes affected 425 million people (including undiagnosed cases) of 
adults aged 20-79 years old around the world in 2017 according to International Diabetes 
Foundation (Figure 12) (100, 101). Although the IDF does not differentiate between Type 1 and 
2 in that figure, the numbers are astounding. The American Diabetes Association reported 29 
million Americans living with Diabetes in (105-108). The disease equally affects developed and 
developing countries where many cases go undiagnosed. Combining RNAi with Fibrillar 
Pharmacology may lead to an innovative option for treating T2DM by alleviating the chronic 
hyperglycemia, major symptom of the disease. 
Diabetes Mellitus (DM) is a noncommunicable metabolic disorder where a person’s 
ability to maintain tightly controlled levels of glucose in their bloodstream diminishes over time. 
Diabetes can be broken into two major categories, Type 1 and Type 2. Many of the current 
treatment options currently available for T2DM attempt to lower blood glucose levels in patients 
and are prescribed in conjunction with each other however their effects are limited (102-104).  
Glucose is the main energy source for the body, requiring tightly controlled homeostasis 
and availability in the bloodstream. A healthy adult maintains serum glucose level at ~100mg/dL 
(5.5mM) with some fluctuations throughout the day and glycosylated hemoglobin (HbA1c) 
<5.5% value, where as a diabetic person has blood glucose levels >126mg/dL (7.0mM) during 
fasting and HbA1c levels >6.5% (109). People with plasma glucose and HbA1c levels in 
between those ranges are pre-Diabetic and are recommended to change their lifestyle (diet and 
exercise regime) to decrease risk of disease progression.  
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Figure 12: Number of cases of adults (20-79) with Diabetes around the world. It is estimated that there were 285 
million people living with Diabetes in 2010 and that number doubled by 2017 to 425 million. The left axis is the 
number of people with Diabetes in the millions. The chart includes both diagnosed and undiagnosed patients, but it 
does not differentiate between Type 1 and Type 2 Diabetes. Image from International Diabetes Foundation. 
 
Insulin and glucacon are key components in maintaining relatively constant blood 
glucose levels by opposing one another. The hormone insulin produced by pancreatic β-cells. 
After a meal the pancreas releases the hormone into the bloodstream causing insulin-sensitive 
tissues, such as the liver and kidneys, to stop endogenous anabolic  metabolism (gluconeogenesis 
and lipolysis) and take up the excess glucose from the environment, thus lowering the blood 
glucose levels and initiate catabolic metabolism (glycogen and fatty acid synthesis)(104, 110). In 
times of need, such as during a fast or exercise, pancreatic α-cells secrete the hormone glucagon 
signaling breakdown of glucose storages stores from glycogen and release glucose into the 
blood. Deregulation of these counteracting hormones upsets the careful control of glucose 
homeostasis.  
Diabetes Mellitus Type 2 as mentioned earlier is a metabolic disorder characterized by 
chronic hyperglycemia and insulin resistance. Unlike T1DM where patients are completely 
unable to produce insulin on their own due to loss of pancreatic β-cell function, T2DM patients 
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can produce insulin, but not sufficient supplies for the needs of the body or tissues that are 
normally sensitive to insulin are resistant to its effects (104, 106, 110, 111). Additionally, as the 
disease progresses insulin sensitive tissues gradually build greater resistance to insulin’s 
presence. As an initial step to battle hyperglycemia and insulin resistance, pancreatic β-cells will 
produce and secrete more insulin (104, 112, 113). However, as time progresses and if 
hyperglycemia is not kept in check by the patient, insulin resistance will gradually increase 
further intensifying the insulin demand from the pancreas. As a result of this slow increase in 
insulin resistance and insulin demand pancreatic β-cells will fail and maintenance of glucose 
concentration in the blood is lost (112). One of the most pernicious aspects of T2DM is that it 
can go undiagnosed for years due to patient being asymptomatic before the patients experiences 
a major hypoglycemic event.  Finally, T2DM can also lead to a range of comorbidities including 
atherosclerosis, hypertension, end stage renal disease, nerve degeneration, cardiovascular 
disease, vision loss, obesity and a lower quality of life. 
Another issue associated prolonged chronic hyperglycemia can lead to increased random 
glycation of protein, lipid or nucleotide called Advanced Glycation End-products (AGE) (114, 
115). Unlike glycosylation where proteins and other molecules are affixed with sugar moieties 
enzymatically at specific locations, glycation is random cross-linking of sugars to amino groups 
of proteins by the Maillard reaction (115). The formation of AGEs appears to be increased in 
diabetic animal models and possibly due to chronic hyperglycemia (115). Recognition of the 
inadvertently glycated proteins by the Receptor for AGEs (RAGE) induces intracellular 
oxidative stress and the expression of proinflammatory genes (114, 115). Prolonged exposure to 
hyperglycemia can have many detrimental effects from the more clearly visible obesity and limb 
amputation to the less noticeable increase in AGE products, hypertension and atherosclerosis.  
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Oral Anti-Hyperglycemic Medications 
The major treatment recommendations prescribed to T2DM patients is a change in 
lifestyle and medication to control blood glucose levels. These treatments provide limited 
success as measured by plasma glucose levels and the long-term blood glucose marker HbA1c 
(116-118). A meta-analysis of 61 studies of patients with HbA1c ranging from 6-11.8% and 
given several different oral glucose lowering medications that acted through insulin concluded 
that fasting plasma glucose levels and HbA1c levels did not reach the target of HbA1c level of 
<6.5% (116). Additionally, people with more extreme HbA1c levels respond better to oral anti-
hyperglycemia medications than those who are in between normal and diabetic (104, 110, 
119).Current oral medications prescribed to treat T2DM either increase the insulin concentration 
in the bloodstream or sensitize tissues to its presence (Table 2). However, as time progresses, 
these insulin dependent treatment options become less and less effective (102, 104, 110). These 
challenges along with the staggering number of current and predicted number of cases of 
diabetes create a substantial demand for an insulin independent mechanism for treating 
hyperglycemia and T2DM. 
Many of the current oral medications for treating T2DM require an insulin dependent 
mechanism of action (117, 118, 120-124). Metformin is the leading medication prescribed to 
patients to alleviate hyperglycemia (125). It functions by reducing hepatic glucose production, 
decreases intestinal glucose absorption and improves insulin sensitivity. Several other major 
classes of oral hyperglycemic medications directly or indirectly induce secretion of insulin from 
the pancreas (secretagogues) including sulfonylureas, meglitinides, GLP-1 analogues, DPP-4 
inhibitors while thiazolidinediones sensitize tissues to the presence of insulin (102, 104, 110). 
Additionally, the excess insulin produced by sulfonylureas and meglitinides during a fast can 
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cause life threatening hypoglycemia by decreasing blood glucose below safe levels (102, 110). 
Dopamine agonists such as bromocriptine reduce hepatic glucose production while switching the 
body to fatty acid metabolism to achieve desired glycemic control (120). Amylin mimetics are 
analogues of amylin, a polypeptide co-secreted along with insulin to help to inhibit glucagon 
secretion which in turn improves gastric emptying (118). 
Table 2: Common anti-hyperglycemic medication classes. 
 
 
As mentioned previously, many of the current anti-hyperglycemic medications rely on an 
insulin dependent mechanism of action. This restricts their usefulness as diabetes progresses and 
insulin resistance becomes more prominent. To counter this patients are co-prescribed multiple 
medications; as many as three medications may be taken by a single patient requiring trial and 
error to customize an effective regime (102, 104, 110). However, this may increase the chances 
of hypoglycemia. Despite this, only marginal decreases of HbA1c levels are achieved and 
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adverse side effects from prescribed medications can impinge on a patient's quality of life (123). 
Finally, in many cases comorbidities can arise limiting the available treatment options that can 
be prescribed (104, 110). 
 
SGLT2 Inhibitors (SGLT2i) 
SGLT2 inhibitors (SGLT2i), also called gliflozins, are a relatively new class of anti-
hyperglycemia drugs that have been FDA approved to treat T2DM. Gliflozins have displayed 
many positive effects including decreasing HbA1c levels, weight, blood pressure and decreased 
risk of cardiovascular disease (126-129). This novel class of drugs inhibits the function of a 
glucose symporter, Sodium dependent GLucose co-transporter 2 (SGLT2). Inhibition of this 
transporter leads to the aforementioned positive markers (126-128, 130-134). Inhibition of 
SGLT2 is an insulin independent mechanism for treating T2DM which has created an uproar in 
development of SGLT2 inhibitors in several pharmaceutical companies. 
SGLT2 inhibitors (SGLT2i) also known as gliflozins competitively inhibit SGLT2 
preventing glucose’s reabsorption in the kidneys (Table 3). Several of the early SGLTi 
developed were based on the drug phlorizin, a naturally occurring product found in the bark of 
fruit trees. Phlorizin competitively inhibits SGLT2 in the PCT preventing reabsorption of 
glucose. Instead the glucose continues through the PCT and collects in the bladder for excretion 
with the urine (glucosuria) (135). The first SGLT2i developed was Tanabe’s T-1095, however 
research on the molecule was discontinued. There are currently three small molecule drugs that 
have been FDA approved to inhibit SGLT2: Canagliflozin (Invokana) from Janssen 
Pharmaceuticals was the first FDA approved SGLT2i followed by Dapagliflozin (Farxiga) from 
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Bristol-Myers Squibb and AstraZeneca and Empagliflozin (Jardiance) from Boehringer-
Ingelheim.  
Table 3: Several current SGLT2 inhibitors in development. 
 
 
Diabetes increases plasma glucose levels and renal glucose reabsorption. Healthy adults 
do not excrete glucose due to renal reabsorption by SGLT2 and other glucose transporters. 
However, a person with diabetes will have increased glucose levels in the blood caused by 
hyperglycemia. Intriguingly renal glucose reabsorption is also increased which further 
exacerbates hyperglycemia (Figure 13). When plasma glucose levels exceed 220mg/dL, the 
maximal transport (Tm) of glucose is reached and diabetic patients will begin experiencing 
glucosuria while maintaining hyperglycemia (136). SGLT2i lower the Tm closer to a healthy 
person thus inducing glucosuria and reduced blood glucose levels (dashed vertical lines in the 
figure). Ultimately, plasma glucose levels are reduced with SGLT2i. 
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Figure 13: The maximum glucose reabsorption is increased in diabetes via SGLT2. In a healthy person the 
kidneys reabsorb glucose displaying no glucose excretion; past this point before glucose begins to be excreted. A 
diabetic person’s maximum reabsorption threshold is increased past 400mg/min before glucose is excreted. SGLT2 
inhibition lowers the glucose reabsorption of a diabetic person to induce glucose excretion to lower plasma glucose 
levels. Image from Jung, Diabetes Metabol J 2014. 
 
Inconsistently, patients prescribed SGLT2i causes only a portion of the daily reabsorb 
glucose is excreted and varies from patient to patient. It is not fully understood why less than 
60% of glucose reabsorption is prevented with SGLT2 inhibitors. Several hypotheses have been 
proposed to explain this trend. One that has been tested was that SGLT1, a member in the same 
glucose symporter family as SGLT2, activity increases and compensates for the loss of SGLT2 
function (137-141). This hypothesis would be consistent with Familial Renal Glucosuria (FRG) 
patients who have mutations in the gene encoding SGLT2 leading to non-functioning protein and 
their varied amount of urinary glucose excretion. Previously it was thought that SGLT1 
reabsorbs <10% of the glucose in the PCT acting only to soak up the remaining glucose in the 
glomerular filtrate not reabsorbed by SGLT2. Using genetic knockout models and mice treated 
with pharmacological agents that cause loss of function in both SGLT2 and SGLT1, a greater 
amount of urinary glucose excretion was seen (138-140). Other glucose transporters present in 
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the PCT may also play a greater role in reabsorption when patients take SGLT2i. Potentially, 
inhibition of both SGLT2 and SGLT1 may lead to a more efficacious method to reduce 
hyperglycemia. 
A potential repercussion of SGLT2i medication is an increase of Diabetic ketoacidosis 
(DKA) events. As patients lose one source of energy in by excreting glucose, the body appears to 
increase lipid oxidization to balance the energy requirements. Lipid oxidation in the liver 
converts fatty acids into ketone bodies that can be released into the blood for other tissues to take 
up and use as an energy source when glucose levels are low for long periods. Bonner et al. 
showed that Sglt2 in pancreatic α -cells of mice acted as glucose sensors triggering the release of 
glucagon (142). Increased glucagon in the plasma in turn causes gluconeogenesis, followed by 
lipid catabolism and ketone body release into the bloodstream. Unfortunately, several groups 
have contested Bonner’s findings and have proposed other hypotheses for euglycemic DKA in 
diabetic patients (143-149). Further studies on the potential adverse and long-term side effects of 
SGLT2 inhibition needs to be made. 
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Chapter 1: Hitachi Vertically Aligned Carbon 
Nanotubes (VACNT) 
 
Introduction 
A wide variety of CNTs are commercially available (i.e. single-walled vs. Multi-walled, 
metallic vs. semiconducting, varying production methods and varying purities) but for clinical 
applications highly homogenous and robust performing CNT are desired. Along with the desired 
quality of the CNT, being able to obtain large quantities of CNTs is another major issue. Hitachi 
Zosen’s Vertically Aligned Carbon Nanotubes (VACNTs) provide a promising base for our 
fibrillar nanoparticle delivery system as VACNTs can be produced abundantly and uniformly. 
VACNTs produced by Hitachi Zosen are claimed by the company to be of greater homogeneity 
and with fewer impurities (i.e. amorphous carbon and metal catalysts) than CNT  produced by 
other production methods (83).  In the case of drug development different batches of CNTs of 
varying quality can greatly influence the chemical, pharmacokinetic and therapeutic properties of 
the drug excipient. 
 Hitachi Zosen claims their production method can be used to mass produce VACNTs for 
applications such as construction by growing the VACNT on A4 sheets of substrate (210mm by 
297mm) en masse (Figure 14). Identifying a reliable synthesis method prior to mass production 
for preclinical testing is needed. Hitachi Zosen’s production method to produce highly uniform 
CNT on a large scale by continuous production on a catalyst impregnated substrate (83, 153). To 
produce vast quantities of VACNTs for those applications the CNTs are “grown” as a “forest” on 
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a substrate on in a continuous production line (Figure 15). Their substrate is an A4 sized sheet of 
210mm*293 mm (8.27 inches*11.69 inches) which can be continuously fed into a furnace. 
Production of VACNTs through a controlled “growth” process on a metal substrate yields a 
“forests” of carbon nanotubes. Other groups have reported uniform production of VACNTs by 
exposing the catalyst impregnated substrate to carbon rich gas to generate VACNTs up to 5um in 
length uniformly (84, 150-152). 
 
Figure 14: Vertically Aligned Carbon Nanotubes (VACNT) produced by Hitachi Zosen. Highly uniform 
VACNT produced by Hitachi Zosen on substrate (Top). The nanotubes produced are 50um*20nm. The VACNT can 
be “grown” on A4 sized sheets in a continuous production method (Bottom right). Image from Hitachi Zosen Corp. 
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Figure 15: Scanning Electron Microscopy image of VACNT forest. VACNT produced are highly uniform and 
can range in lengths from >5um. Image from Szabó. Materials. 2019. 
 
Although their production method is proprietary it can be surmised from other groups 
that are developing methods to produce VACNTs that Hitachi Zosen’s production method 
involves several factors (84, 154-159, 159-162). Based on other groups doing similar research, a 
stainless-steel substrate impregnated with a catalyst (i.e. iron oxide or silicon oxide) can be fed 
continuously into a furnace. The VACNT are highly likely grown by chemical vapor deposition 
where a carbon rich gas is flowed over the substrate. And finally, the exposure time to the gas 
can limit the lengths of the VACNT. The growth process is likely to require little time as 
Guzman de Villoria showed that 0.5mm long VACNTs could be grown in 5 minutes in a 
continuously fed furnace (161, 162).  
 VACNTs may provide an ideal source of carbon nanotubes for Fibrillar Pharmacology. 
Their high aspect ratios and strong physical characteristics may allow them to behave similarly 
to the single-walled carbon nanotubes our group has previously studied. Their high purity may 
improve the chemical functionalization reaction and produce a higher chemical yield. 
Furthermore, their superior size and surface area may allow more siRNA molecules to bind onto 
their surface and an augment gene silencing efficacy. However, their greater lengths of more 
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than 1um may influence its pharmacokinetic profile and impede clearance in vivo. The cellular 
toxicity of these larger nanoparticles will also need to be assessed. 
In this chapter we looked at the prospect of utilizing the VACNTs produced by Hitachi 
Zosen as a potential source of CNT as an RNAi delivery excipient. A sample of VACNT was 
graciously donated by Hitachi Zosen for study. The VACNT was chemically functionalized to 
present ammonium moieties on its surface using chemistries previously published (91, 96, 97), 
the product’s physical and chemical properties characterized, and pharmacokinetic profile were 
assayed by radio tracer labeling in vivo. Finally, results of binding of fVACNT with fluorophore 
labeled siRNA show that binding with a small expression vector could potentially lead to an in 
vivo gene therapy with the fVACNT as a delivery vehicle. 
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Materials and Methods 
 
Hitachi VACNT Chemical Functionalization 
The VACNTs were chemically functionalized by adding 18mg of VACNTs to 250mL 
N,N-Dimethylformamide (DMF) and reacted at 130 ˚C under argon gas for six days, each day 
0.5g paraformaldehyde (PFA) and 1g 2-(2-(2-(2-(-tert-butoxycarbonyl) aminoethoxy) ethoxy) 
ethylamino) acetic acid) (Boc-amine) were added to the reaction vessel. After the sixth day, the 
mother liquor containing VACNT-amine-Boc was decanted and filtered using a 0.2um PTFE 
filter and washed three times with DMF. The DMF was evaporated using a rotovap and the 
brown residue was resuspended in chloroform. The chloroform containing VACNT-amine-Boc 
was poured into a separatory funnel and washed several times with distilled water before being 
dried with anhydrous sodium sulfate. The sodium sulfate was vacuum filtered, and the 
chloroform evaporated leaving behind a brown residue that was dissolved in methanol and 
precipitated with ice cold diethyl ether and washed with more ether. 
The Boc protection group was removed from VACNT-amine-Boc by stirring with 20mL 
trifluoracetic acid (TFA) at room temperature for 1 hour to produce VACNT-amine (fVACNT). 
The TFA was evaporated and the fVACNTs were precipitated again with methanol and cold 
diethyl ether and the precipitated was collected by vacuum filtration. The product was 
resuspended in distilled water and was further purified using C18 Sep-Pak cartridges (Waters 
part no. WAT020515) and eluted 50% acetonitrile in water. The acetonitrile was evaporated and 
the fVACNTs were dialyzed against distilled water to remove free amine that was carried over 
from the functionalization reaction in dialysis cassettes (MWCO 3.5kDa). 
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Physical Characterization of fVACNT 
The concentration of the fVACNTs was determined with a SpectraMax M2 UV/Vis 
spectrophotometer using the extinction coefficient (1 g/L = 1.251 AU at 600nm). The amine 
content of the fVACNTs was assayed using Sarin assay with a glycine standard curve with a 
Kaiser Assay kit (Sigma 60017) and a glycine standard curve. Briefly, the ammonium 
functionalized nanoparticle was aliquoted into an eppendorf tube and the volume raised up to 
100uL with distilled water. To each eppendorf tube 100uL 95% ethanol was added followed by 
50uL phenol, 50uL potassium cyanide and 50uL ninhydrin. The eppendorf tubes were heated at 
95˚˚C for 5 minutes then cooled to room temperature. On a clear 96-well flat bottom plate 150uL 
50% ethanol was pipetted and 50uL of the reaction was added. The absorbance of the ninhydrin 
product was then measured on a SpectraMax M2 UV/Vis spectrophotometer at 570nm with 
SoftMaxPro v5.0.1 software. A glycine standard curve was generated alongside of the samples 
each time the assay was done. The absorbance measurements of all samples were measured in 
triplicate. 
The purity of fVACNTs was determined by reverse phase HPLC, 20ug fVACNTs was 
injected into a Shimadzu HPLC system (SIL-20AC autosampler, LC-20AB liquid 
chromatograph, SPD-M20A photodiode array, SPD-20AV UV/Vis detector, RF-20A xs 
fluorescence detector and CBM-20A communications bus) with a C18 reverse phase column 
(Phenomenex Gemini 5u C18 110A, p/no. 00G-4435-E0) using 20mM sodium acetate, 150mM 
NaCl, 0.2% sodium azide pH 6.8 and acetonitrile as mobile phases. The concentration of 
acetonitrile was increased from 0-100% over 30 minutes. The fVACNTs elution was monitored 
by its absorbance at 330nm and its fluorescence using excitation at 405nm and emission at 
515nm. Also, 20ug fVACNTs was analyzed by size exclusion HPLC on the same HPLC system 
39 
 
with a Superdex 200 column (Superdex 200 10/300 GL, code no. 17-5175-01) and 20mM 
sodium acetate with 150mM NaCl and 0.2% sodium azide as the mobile phase using the same 
wavelengths for detection as in reverse phase HPLC. 
 
Radiotracer Labeling and In vivo Biodistribution of [
111
In]DOTA-VACNT 
Ammonium functionalized VACNTs were conjugated with DOTA-
111
Indium, 
[
111
In]DOTA-VACNT and injected into 3 10-month-old female C57Bl/6N mice. Each mouse 
received 3μCi of the radiolabeled fVACNTs in a volume of 95uL via retro-orbital injection. The 
mice were sacrificed 1-hour post injection and the blood, heart, lungs, liver, kidneys, stomach, 
small and large intestines, spleen, muscle, bone brain, salivary glands and urine were collected. 
Each tissue was weighed, and the radioactivity was counted with a Packard Cobra II Auto-
gamma counter. The radioactivity counts were normalized to 20uL standards of 
111
Indium. 
 
Titration of fVACNT with siRNA-Cy3 
To determine the binding affinity of fVACNTs to duplex siRNA the fVACNTs was 
titrated with the fluorophore Cyanine 3 (C3) labeled siRNA in a Varian Cary Eclipse 
Fluorescence Spectrophotometer as previously described (96). Briefly, 5uL 192.8ng/ul Cy3 
labeled mouse Sglt2 siRNA (sequences are in the Appendix) was diluted with 535uL RNase free 
water and 60uL 10x PBS (26mM KCl, 100mM Na2HPO4, 17.6mM KH2PHO4 and 125mM NaCl 
pH7.4) for a final volume of 600uL. fVACNT was added to the solution causing quenching of 
Cy3 fluorescence and measurements were taken in triplicate for each addition of fVACNTs. The 
titration was conducted at 37˚C. The sequences of the siRNA were Cy3 labeled mouse Sglt2 (see 
Appendix for sequences). For the calculations the molecular weight of the fVACNT was 
assumed to be 2,000,000 Daltons. The binding affinity was determined by plotting ΔF/F0 vs log 
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[fVACNT] and the stoichiometry of siRNA: fVACNT was determined by plotting F/F0 vs log 
(mole ratio siRNA: fCNT). Data was analyzed on Excel and plotted using GraphPad Prism 7. 
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Results 
 
Hitachi VACNT Chemical Functionalization and Physical Characterization 
Hitachi Zosen supplied VACNTs on a stainless aluminum sheet and dissociated from the 
sheet readily by washing with absolute ethanol. The nanotubes were dried by vacuum filtration 
and the weight was measured to be 292mg. The VACNTs may have still contained ethanol. The 
VACNTs were left under vacuum to dry overnight and the next day 18mg VACNTs were used 
for amine functionalization reaction. 
 
Figure 16: Ammonium functionalization reaction of carbon nanotubes. Pristine VACNT were reacted with Boc-
Peg-Glycine for 5 days at 130°C. The Boc protected product was purified and then deprotected with Trifluoroacetic 
acid (TFA) to yield the ammonium functionalized carbon nanotube. The VACNT are multi-walled CNT but shown 
in image is a single-walled carbon nanotube. 
 
The VACNT were ammonium functionalized by 1,3 dipolar cycloaddition by azomethine 
ylide reaction (Figure 16) (91, 96, 97, 163). The functionalization reaction yielded 5.53mg 
fVACNTs (30.7% yield) measured by UV/Vis absorbance at 600nm with the extinction 
coefficient 1g/L = 1.251 AU. The yield was higher than previously reported yields with the same 
reaction with HiPCO (High Pressure Carbon monoxide) (96) and CoMoCat (Cobalt 
Molybdenum Catalysis) (unpublished data) single wall CNTs. Increased yield was possibly due 
to the higher purity and homogeneity of the multi-walled VACNT compared to the other two 
types of carbon nanotubes. 
Although the multi-walled VACNTs have greater surface area than single-walled HiPCO 
and CoMoCat nanotubes the Kaiser assay showed that they have similar amine content per gram 
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of fCNT (Table 4). The assay showed that fVACNTs have 0.54mmol amine/g nanotubes while 
HiPCO have 0.3-0.5mmol/g (96) and CoMoCat nanotubes have 0.50mmol amine/g. In all 
calculations it was assumed that the molecular weight of the VACNTs was 2 million Daltons. 
While they have similar amine content per gram of nanotubes the VACNTs have nearly 10-fold 
increase in the number of ammonium sites per nanotube due to their greater molecular weight 
and therefore fewer molecules for the same mass. 
Table 4: Summary of ammonium Functionalization Reactions between Hitachi fVACNTs, CoMoCat fCNT 
and HiPCO fCNT. Data for HiPCO fCNT is from published work (Alidori. J Phys Chem 2013) 
 Hitachi fVACNTs CoMoCat fCNT HiPCO fCNT 
Reaction starting mass (mg) 18mg N/D N/D 
Reaction yield (mg) 5.53mg N/D N/D 
Reaction yield % 30.70% ~2% ~10% 
Amine content (mmol/g) 0.54mmol/g 0.5mmol/g 0.3-0.5mmol/g 
Estimated dimensions 1100nm*12nm 300nm*1nm 300nm*1nm 
Estimated surface area 
(Acylinder = 2πrh) 
~84000nm
2
 ~2000nm
2
 ~2000nm
2
 
Estimated mmol 
amine/nanotube 
6.50*10
-17
 mmol 
amine/fCNT 
9.03*10
-18
 mmol amine/fCNT N/D 
Estimated molecular mass 
(Daltons) 
2,000,000 300,000 300,000 
 
The functionalized VACNTs were evaluated by reverse phase and size exclusion HPLC. 
Using a C18 reverse phase column, the fVACNTs showed a single species with a retention time 
of 16 minutes (45% acetonitrile) (Figure 17) like HiPCO and CoMoCat nanotubes. (~40% 
acetonitrile). The fVACNT appear to be >90% pure from the HPLC spectra with a small amount 
of impurity that eluted at approximately 5 minutes and there was a fluorescent peak at 10 
minutes, but it did not have UV/Vis absorbance. Together this data shows that the fVACNTs are 
of high purity and can be used for further biological studies. 
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Figure 17: Reverse phase HPLC of fVACNT. fVACNT eluted as a single peak at ~45% acetonitrile (~15 minutes) 
showing >95% purity. UV/Vis absorbance was measured at 330nm and fluorescence detector was set at 405nm 
excitation and 515nm emission.  
 
Currently the molecular weight of the VACNTs has not been determined empirically. 
Estimates yield results between 2 million Daltons upwards of 157 million Daltons depending on 
the method of calculation (Table 5). The lower estimate of 2 million Daltons is based on the 
scaling of single wall nanotubes (300nm by 1nm) having a molecular weight of 300 kDa to the 
size of the fVACNTs (1100nm by 12nm). While the 137 million estimate is based on the using a 
density coefficient (2.1g/cm
3
) and the volume of the VACNT (164). In any case, it is difficult to 
accurately calculate molecular weight as the VACNT is multi-walled and the exact number of 
walls is also not known, further complicating calculation methods. 
 On size exclusion HPLC the fVACNTs eluted late at 40 minutes, counter-intuitively as it 
is a large macromolecule with an estimated weight in the millions of Daltons (Figure 18). The 
late elution time on size exclusion HPLC is characteristic of small molecules, not large 
macromolecules. High molecular weight molecules ideally elute early on a size exclusion 
column as the larger molecules are not retarded by the column packing. This behavior has 
previously been seen where long fibrillar molecules that can align with the porous filtration 
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medium of the size exclusion column (90). In Ruggiero’s work he showed that high aspect ratio 
molecules such as fibrillar nanoparticles can align with the flow of the medium, rather than 
tumbling like a spherical molecule, allowing the particles to move lengthwise with the direction 
of the flow, like canoe in a fast moving in a fast stream. A model was proposed for this 
phenomenon but the upper limit in dimensions and molecular weight of fibrillar molecules with 
this unique behavior is not known. 
Table 5: Molecular weight estimations of fVACNTs. Molecular weight of VACNT was estimated using two 
different methods: the first was “Scaling up weight” as if the VACNT was a rolled-up sheet to form a cylinder. The 
surface area of that sheet was calculated and then its molecular weight was determined by scaling up from the 
weight CoMoCat fCNT of 300kDa. The second method was calculated using a skeletal density coefficient (D = 
2.1g/cm
3
) found in the literature (Lehman. Carbon 2011). The volume of the VACNT was first calculated nm
3
 and 
then converted to cm
3
. Neither of these methods considers the number of walls the VACNT contains. 
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Figure 18: Size exclusion HPLC of fVACNT. fVACNT was analyzed by SEC HPLC the UV/Vis spectra (left) and 
fluorescence (right) were monitored to examine its elution profile. The fibrillar fVACNT (black trace) elute late on a 
size exclusion column demonstrating small molecule behavior even though their molecular weight is >1million 
Daltons. Standards were run on the same column to estimate the molecular weight of the fVACNT. Mouse IgG (red 
IgG trace on chromatogram) was conjugated with DyLight650 and has a molecular weight of ~150kDa and 
AlexaFluor488 (green trace) has a molecular weight of 650Da. 
  
In vivo Biodistribution of [
111
In]DOTA-VACNT 
The fVACNTs were radiotracer labeled with Indium-111 and injected into 3 female 
C57Bl/6N mice. One hour after injection the mice were sacrificed, and major tissues were 
harvested to analyze uptake of the radiolabeled fVACNT by gamma counting. The majority of 
the radiolabeled fVACNT cleared the blood (with only 5% remaining at the time of sacrifice) 
and was excreted into the urine indicating quick clearance (Figure 20). Again, this result is quite 
remarkable as the molecular weight and size of the fVACNT would lead one to believe that the 
kidneys would not be capable of filtering the large macromolecule which would instead be 
retained when filtered by the kidneys.  
Therapeutic antibody drugs with molecular weights of ~150kDa can circulate in the 
blood stream for weeks post injection due to the filtering ability of the glomerulus in the kidneys 
(93, 94). Only about 5% of the radioactivity remained in the blood while the kidneys contained 
about 13% and the liver ~10% of the fVACNTs at this timepoint. The fVACNT cleared slower 
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than functionalized single-walled carbon nanotubes which clear the blood compartment by 1-
hour. The tissue radioactivity counts here may be higher than they actually are due to the 
contribution of the blood activity in the tissues. Uptake in the kidneys and liver provide potential 
tissue-specific delivery of therapeutic cargo by the fVACNT.   
 
Figure 19: Radiotracer labeling of fVACNT with [
111
In] DOTA. Indium-111 was chelated to DOTA-Bz-NCS at 
58°C pH 5.5 prior to conjugation with ammonium functionalized VACNT. The reaction was quenched and purified 
yielding the radiolabeled fVACNT. The radiolabeled conjugate was injected into mice to measure uptake of the 
nanoparticle. 
 
 
Figure 20: Radiotracer biodistribution of fVACNT displaying fast blood clearance. Three mice were injected 
with radiolabeled fVACNT and euthanized 1-hour post injection. Tissues were harvested, weighed and activity was 
counted (left panel). At the 1-hour timepoint radioactivity did not completely clear the blood (~5% remaining) (right 
panel). Majority of the radioactivity was excreted in the urine (>95%) while there was ~12% ID/g uptake in the 
kidneys and 10% in the liver. Other tissues showed minimal uptake. 
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Binding of fVACNT with siRNA-Cy3 
The fVACNTs were titrated with siRNA to measure binding affinity and stoichiometry. 
As the concentration of the fVACNT increase the siRNA’s anionic phosphate groups can form 
electrostatic interactions with the cationic ammonium groups on the surface of the fVACNT 
(96). SiRNA was conjugated with the fluorophore Cyanine 3 (Cy3). As the fluorophore labeled 
siRNA bind to the fVACNT, Cy3 fluorescence is quenched by the electronic properties of the 
nanotube. For the calculations the molecular mass of the fVACNT was assumed to be 2 million 
Daltons. The Cy3 fluorophore was excited at 550nm and emission was detected at 565nm. 
Fitting of the data showed that the nanotube had a sub-nanomolar binding affinity with the 
siRNA-Cy3 and there were approximately 25 siRNA per nanotube (Figure 21). The binding 
affinity and stoichiometry for the 13.2 million and 157 million Dalton weight estimations were 
also calculated (Table 6). 
 
Figure 21: fVACNT titration with siRNA-Cy3. fVACNT and fluorophore labeled siRNA-Cy3 bind through 
electrostatic interactions with <1nM affinity and at a ratio of 25:1 siRNA: fVANCT. Calculations here used 2 
million Daltons as the molecular weight of the fVACNT. 
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Discussion 
 
Vertically Aligned Carbon Nanotubes from Hitachi Zosen were chemically 
functionalized and characterized. Based on a TEM image supplied by Hitachi, pristine VACNT 
are approximately 1um by 12nm (Data not shown). These nanotubes are substantially larger than 
the CNTs we have previously worked with (96). Although we currently do not have 
experimental data on the molecular weight of the VACNT estimations where calculated using 
several different methods. The multi-walled VACNT were calculated to be either 2 million 
Daltons, ~13.2 million Daltons or up to 157 million Daltons depending on the calculation 
method (Tables 5 and 6). In all experimental data it was assumed that the fVACNTs’ molecular 
weight was 2 million Daltons for calculations. These estimations of the VACNT molecular 
weight are highly variable and greatly affect the calculations for siRNA-Cy3 binding affinity and 
stoichiometry. An empirical method would need to be used to determine the weight accurately.  
Table 6: fVACNT estimated molecular weights and binding affinity with siRNA-Cy3. Binding affinity and 
stoichiometry were recalculated using the other estimations for fVACNT molecular weight. 
Estimation 
method 
Estimated 
molecular weight 
(Da) 
Estimated Kd 
titration (at pH 7) 
Estimated number 
of bound siRNA 
Estimated number of 
nucleotides bound 
Scaling up 2 million 0.67nM 25 525bp 
Unrolled sheet 13.2 million 0.10nM 126 3400bp 
Using skeletal 
density coefficient 
157 million 8.498*10
-12
M N/D N/D 
 
The fVACNTs have similar ammonium content as other fCNT on size exclusion HPLC. 
The biodistribution of Indium-111 labeled fVACNTs showed that most of the injected 
radioactivity was excreted 1-hour post injection with only 5% remaining in the blood, which 
contributed to the activity in the other tissues. There was no uptake in the brain, lungs or muscles 
assuaging some of the fears of pulmonary and other toxicities that carbon nanotubes may 
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potentially cause (165-171). The kidneys and liver retained ~13% and 10% of the radioactivity, 
respectively. This was unexpected as the fVACNTs are macromolecules approximately 2 million 
Daltons but were capable of filtering through the kidneys. 
Unlike large globular proteins, which are retained during blood filtration in the nephrons, 
the high aspect ratio of the fVACNTs (~90:1) allows the fibrillar nanoparticle to align with the 
flow of the blood, clear the glomerulus and collect in the bladder for excretion. This provides a 
unique pharmacokinetic profile for fibrillar nanoparticles that can be exploited in delivering 
potentially cytotoxic drugs to the kidneys. The fVACNT-drug complex may be able to be taken 
up at a therapeutic dose and the excess clearing from the blood quickly, decreasing exposure of 
the kidneys to cytotoxic compounds. 
Titration with siRNA labeled with the fluorophore Cyanine (Cy3) showed fVACNT can 
bind multiple siRNA per carbon nanotube molecule. With the assumption that the fVACNTs 
have a molecular weight of 2 million Daltons, titration of fVACNT with Cy3-labelled siRNA 
showed that potentially 25 siRNA molecules bound to each nanotube with a binding affinity of 
0.67nM. Using the molecular weight values obtained from the other calculation methods yielded 
higher siRNA: fVACNT ratios and stronger binding. This implies that the larger the ammonium 
functionalized carbon nanotube, the more siRNA it can carry while still being able to clear from 
the blood compartment relatively quickly. The maximum dimensions and molecular weight of 
this nanotube needs to be determined the upper limit in the number of siRNA copies a single 
carbon nanotube can carry. 
Another conceivable application for ammonium functionalized VACNTs may be to 
transport a small exogenous gene to express a protein of interest in the kidneys or liver. In this 
work fVACNT were seen to bind roughly 25 copies of siRNA or 525 nucleotide base pairs (25 
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siRNA * 21 base pairs for each siRNA = 525 base pairs). Rather than binding a dozen or two 
siRNAs, the fVACNT can feasibly bind one or two expression plasmids of a similar number of 
base pairs. Binding a larger plasmid may be possible as a circular plasmid could supercoil thus 
requiring less surface area of the fVACNT to bind onto. Targeted gene delivery in the kidneys or 
liver could provide an approach to treat metabolic disorders where patients lack a functioning 
allele. The delivered gene could then supply the deficient gene as a surrogate but size of the gene 
that would be delivered would still be limited. 
 
Figure 22: Generation of Minicircle DNA from parental bacterial plasmid. Addition of arabinose to bacterial 
culture producing the parental plasmid will induce excision of the minicircle DNA. This forms two now vectors: the 
desired Minicircle expression vector and the bacterial backbone plasmid. The Minicircle can then be purified and 
introduced into a eukaryotic expression system. 
 
To overcome the maximum size of a gene the fVACNT can Minicircle DNA technology 
could be exploited. A Minicircle DNA greatly reduces the required segments of an expression 
vector by removing the irrelevant sequences and containing only the foreign gene of interest 
along with a promoter for gene expression (172-176). The Minicircle DNA is derived from a 
parental bacterial vector (Figure 22). Bacterial DNA replication machinery is exploited to 
expand the copies of the vector and consequently the Minicircle DNA. The when induced the 
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parental vector excises the Minicircle DNA leaving behind two circular vectors: the backbone of 
the parental plasmid and the newly formed Minicircle. The Minicircle can then be purified and 
delivered in vivo, in vitro or in this case bound to the fVANCT for targeted tissue delivery. 
Initially, in a proof of concept experiment introduce eGFP (~700 base pairs) or Firefly luciferase 
(~1650 base pairs) with the fVACNT in vivo or in vitro. These genes are within the calculated 
size limits of fVACNT binding and would provide an easily detectable protein product through 
imaging and Western blot.  The fVACNT could potentially be utilized as a gene delivery system 
as well as an excipient for gene silencing.  
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Chapter 2: Cellulose Nanocrystals (CNC) 
Introduction 
In this chapter we look at the use of Cellulose Nanocrystals (CNC) as an alternative to 
carbon nanotubes in RNAi delivery. Unlike carbon nanotubes which are produced commercially 
in chemical reactors, CNCs are derived from cellulose rich materials such as wood pulp and 
other plants. Previous work utilized Carbon Nanotubes (CNTs) as delivery vehicles with 
covalently and/or non-covalently appended drugs/reporters, however CNTs can be an expensive 
nanomaterial to acquire and as mentioned previously there are many variations between sources 
and batches of nanotubes. CNC show robust uniformity, strength and high aspect ratios, all 
features that are desired in fibrillar RNAi delivery platforms. Here, pristine CNC were 
chemically functionalized, their physical and pharmacokinetic properties studied and in vivo and 
in vitro gene knockdown were completed to show CNCs as another potential fibrillar 
nanoparticle delivery system for RNAi. 
 
Figure 23: Cellulose structure. Individual β D-glucose units are connected to successive units through β-1,4-
gylcosidic bonds to form linear cellulose chains. Lateral association between cellulose chains are mediated through 
an extensive hydrogen bond network. Image from http://www.ethanolproducer.com/articles/10339/demystifying-
cellulose. 
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Cellulose is an abundant polymer of D-glucose produced in plants as a method to store 
glucose analogous to glycogen in animals. In glycogen the D-glucose units are linked by α-1,4 
glycosidic linkages and have a great deal of branching at about every 8-12 residues making it 
highly water soluble (177). Conversely, cellulose contains hundreds of D-glucose units linked by 
β-1,4 glycosidic linkages forming a linear polymer. This produces long chains of cellulose that 
can associate laterally and form an extensive intermolecular hydrogen bond network, excluding 
water molecules from the assembly (Figure 23). This difference in linkage type makes cellulose 
indigestible by most animals unless they express cellulose enzymes or are ruminants with 
symbiotic bacteria that breakdown the cellulose in their guts (181-183). This makes CNCs a 
robust material for drug delivery that cannot be degraded in the blood or intracellular 
environment while still maintaining its fibrillar aspects and behavior. 
 
Figure 24: From glucose molecules to cell walls of a tree. Two glucose molecules are joined together by B-1,4-
glycosidic bonds. Hundreds of glucose residues joined together this way forms a cellulose chain and when stacked 
laterally, the chains can form sheets through hydrogen bonding and van der Waals interactions. Many sheets can 
stack to form Cellulose Nanocrystals which contain crystalline and amorphous regions. Many cellulose nanocrystals 
pack together to form protofibrils, then microfibrils before becoming cellulose fibrils which finally form the cell 
walls of trees. Image from Sinko ACS Macro Lett 2014. 
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CNCs are a highly ordered polymer of cellulose chains. Individual chains of cellulose, 
containing hundreds of glucose units coupled consecutively, can come together and form 
protofibrils laterally held collectively by van der Waals interactions and an extensive hydrogen 
boding network (Figure 24) (178-180). In turn the protofibrils can form microfibrils and then 
cellulose fibers. The cellulose fibers contain crystalline and amorphous regions; this work 
involves the rod-like crystalline regions for study. The amorphous regions are more susceptible 
to acid hydrolysis than the crystalline CNC regions (179). It is these acid resistant regions that 
give cellulose its morphology and unique physical properties. Cellulose is highly rigid and 
possesses great tensile strength while being low density, allowing trees to grow dozens of feet 
tall. Additionally, the CNC maintain the rod-like nature of cellulose where the lengths of the 
CNC are dependent on the degree of polymerization (DP). Depending on the source material of 
the cellulose and therefore the CNC, the DP and length can vary. For example, cellulose from 
wood pulps can range from 100-200nm in length while cotton can range from 100-300nm and 
bacterial CNCs can be from 100-1000nm (179). Furthermore, the time spent to hydrolyze the 
cellulose can affect the length of the CNC. 
To produce CNC, cellulose must be mechanically and chemically broken down. 
Hydrolysis with sulfuric acid will convert some of the alcohol groups into anionic sulfate groups 
while hydrolysis with hydrochloric acid will leave behind carboxylic groups. Also, further 
oxidation of the alcohol groups can generate increased carboxylic content. These anionic groups 
as well at the innate primary and secondary alcohol groups of the CNC give rise to a variety of 
possible chemistries that can be applied to the CNC (179).  
Their fibrillar nature, robust physical properties and assortment of chemical 
manipulations make CNCs a prospective nanoparticle for drug delivery. However, the lack of 
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degradation mechanisms of CNCs also raises question about safety issues of CNCs as a 
therapeutic agent if the drug is taken chronically. Cellulose nanocrystals have been used in the 
food, cosmetic, paint and paper industries as a filler material or to add desired texture to the 
products (184-186). In the food industry it has been used as a “zero-calorie 
filler/thickener/stabilizer” additive in many foods, indicating its non-toxic properties in the 
gastrointestinal system (185). However, injection of a non-degradable nanoparticle into the 
bloodstream and prolonged cellular uptake of the particles is a completely different safety issue. 
Injecting a foreign particle produced in plants that cannot be degraded can produce a response by 
the immune system may cause health issues that are not seen when CNCs are ingested.  
Currently the focus of CNC toxicity is within the lungs and skin exposure (187-190). 
Several in vitro and in vivo studies have claimed potential genotoxic and pulmonary toxicity; 
however, those studies should be taken with a grain of salt (187, 190, 191). In Shvedova’s work, 
the authors utilized a single large bolus of CNC given to mice and did not account for body 
weight differences between male and female mice (192). In addition, these studies have been 
conducted using pristine water insoluble CNC. Water soluble nanoparticles may have 
significantly different pharmacokinetic profiles compared to their insoluble precursors. Fast 
clearance from the blood can be a possible way to minimize toxic effects of the CNCs by 
preventing the long circulation times in plasma. Furthermore, the effect of accumulation of the 
CNC within cells and tissues is unknown. Extensive long term studies of water soluble and 
insoluble forms of functionalized CNC (fCNC) need to be made before conclusion can be drawn. 
CNC are an ideal fibrillar nanoparticle due to their physical properties as well as their 
inherent abundance. Below are the prices of CoMoCat single-walled nanotubes and Cellulose 
nanocrystals (Table 7). Bulk CNC slurry can be as cheap as $1/gram even when the 8.0% w/w 
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concentration of the CNC is considered (1kg CNC slurry = 80g CNC) at the lowest price point 
the CNC are $12.50 per gram, still making the CNCs an order of magnitude lower in cost than 
carbon nanotubes. 
Table 7: Price comparison between CNT and CNC. The Cellulose nanocrystals are supplied as an 8.0% w/w 
slurry the first number under its price is the amount offered and the “Price per gram” considers the 8.0% w/w. Prices 
are correct as of June 2019. 
Nanomaterial Vendor Price Price per gram 
Carbon nanotubes 
(CoMoCat cat #704113) 
Sigma Aldrich $714 per gram 
Cellulose nanocrystals 
(BGB Ultra (8.0% w/w)) 
Blue Goose Biorefineries 
$100 per 74 grams $16.89 
$148 per 148 grams $16.89 
$1000 per kilogram $12.50 
 
After a reliable vendor has been sourced for the nanomaterial, in vitro and in vivo testing 
delivery of the active drug can begin. In the previous chapter VACNT nanoparticles were 
sourced, chemically modified and preliminary physical characterization was done as an initial 
stage of developing a fibrillar nanoparticle drug delivery system. In this chapter we proceed past 
the chemical functionalization of cellulose nanotubes and begin in vitro and in vivo gene 
knockdown experiments. 
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Materials and Methods 
 
Chemical Functionalization of CNC 
Two samples of Cellulose Nanocrystals were supplied by Blue Goose Biorefineries: BGB 
Natural (7.4% w/v; lot# ANN05-004) and BGB Ultra (8.0% w/v; lot# AUU06-006). BGB 
Natural was used to synthesize BG1, while BG2, BG2a and BG3 was produced using BGB Ultra 
as a starting material. 
Cellulose Nanocrystals, BGB Natural (7.4%) were iodinated prior to being reacted with 
epichlorohydrin (ECH) and 2,2′-(Ethylenedioxy)bis(ethylamine) (EBEA) to generate the 
ammonium functionalized product. A sample of BGB Natural was dried under vacuum leaving 
behind 0.46g solid CNC. The dried CNC was suspended in anhydrous pyridine and cooled to -
15˚C before the addition of 1g 2,4,3-trichlorobenzensulphonyl chloride. The ammonium 
functionalized result was later named BG1. 
A sample of CNC (BGB Ultra 8.0% w/w) from Blue Goose Biorefineries Inc. was 
provided as a slurry. In 20mL 1M ammonium acetate 109mg of CNC was dispersed. To the CNC 
solution 946mg of N-3-(dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride (EDC) in 
2mL water was added at room temperature then 5 minutes later 897mg EBEA was added and 
stirred overnight at room temperature. The next day the reaction mixture was dialyzed against 
water to remove remaining reactants. This product was later named BG2. 
A second amination reaction was performed on an aliquot of BG2 to increase its water 
solubility; this product was later called BG2a. To 18mL BG2 (338.4mg) the pH was adjusted to 
pH 5.5 with 10M ammonium acetate to a final concentration of 1M ammonium acetate. Then 
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2.94g EDC and 2.74mL (2.78g) EBEA was added to the reaction. The reaction was stirred at 
room temperature overnight and then dialyzed against water. 
To produce BG3, 15g of BGB Ultra (7.7*10
-4
 moles glucose) resuspended in 20mL water 
and sonicated for 20 minutes then the pH was adjusted to pH 11 with 8N NaOH. To the CNC, 
427mg ECH (2 molar equivalents of glucose * 3 hydroxyl groups per glucose unit) was added 
and allowed to react at room temperature for 4 days before being dialyzed against water in a 
dialysis cassette (MWCO 3.5kDa). To the epoxide containing cellulose nanocrystals 2 molar 
equivalents of EBEA was added to reaction and stirred overnight. 
 
Physical Characterization of Functionalized CNC (fCNC) 
The amine content of the cellulose nanocrystals was determined by Sarin assay as 
previously described. A fluorescent derivative of BG1 was made to analyze by size exclusion 
HPLC. The BG1 conjugated with AlexaFluor488 (AF488) was analyzed on HPLC equipped 
with a size exclusion column with 20mM sodium acetate buffer with 150mM NaCl and 0.02% 
sodium azide. Elution of BG1-AF488 was monitored by the UV absorbance at 495nm and the 
fluorescence excitation at 495nm and 519nm emission spectra. 
         Dynamic Light Scattering was experiments were conducted on the pristine CNC and the 
amine functionalized CNC products to measure their hydrodynamic radius and zeta potentials on 
a Malvern Zetasizer Nano Z. Samples were diluted to 0.1mg/mL and sonicated prior to analysis. 
The Refractive index was set to 1.470 and Absorptivity to 0.01 for the measurements. For zeta 
potential measurements 0.1mg/mL samples were placed into Malvern DTS1070 cuvettes. 
Additionally, dilute samples of BG Natural, BG Ultra, BG1 and BG3 were titrated with 0.1N 
NaOH and 0.1N HCl. The data was exported, analyzed and plotted on Excel and GraphPad 
Prism 7. 
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 The CNC morphologies were analyzed by Transmission Electron Microscope (TEM) and 
Atomic Force Microscopy (AFM). TEM images were taken using JEOL JEM 1400 Transmission 
Electron Microscope with 1mg/mL samples of BG Natural or BG1. The instrument has an 
accelerating voltage up to 120kV with an equipped CCD camera. The samples were spotted onto 
formvar-coated copper grids. Multiple images of each sample were taken to measure their length, 
diameter and general shape. AFM images were taken of 0.1mg/mL samples of BG Natural or 
BG1 diluted 1:100 and 40uL was spotted onto freshly cut mica, allowed to stand for 30min and 
then air dried under a stream of nitrogen. The AFM instrument was an MFP-3D-BIO equipped 
with an Olympus AC240TS-R3 AFM probe and set to tapping mode at ambient temperature. 
Images were taken, and then individual particles were analyzed to determine their height and 
lengths. 
 
Radiotracer Labeling and In vivo Biodistribution of [
225
Ac]DOTA-BG1 
To determine the biodistribution of BG1 in vivo BG1 was 
225
Actinium radiolabeled 
([
225
Ac]DOTA-BG1), injected into mice and their tissues harvested and counted (Figure 25). 
Briefly, 1mCi 
225
Ac was chelated with 1.15mg 1,4,7,10-tetraazacyclododoecane tetraacetic acid 
(DOTA-Bz-SCN). The pH was adjusted to pH5.5 with 2M tetramethylammonium acetate and L-
ascorbic acid before being heated at 58˚C for 30min. After the 30min chelation reaction, 3mg 
BG1 was added to the reaction and the pH was raised to pH 9.5 with 1M bicarbonate buffer and 
heated at 37˚C for 75min. To quench the reaction 0.02mL diethylenetriaminepentaacetic acid 
(DTPA) was added to the reaction and the product was purified by size exclusion 
chromatography with P6 resin as the stationary phase and 1% Human Serum Albumin in 0.9% 
NaCl as the mobile phase. 
60 
 
 
Figure 25: Radiotracer labeling of BG1 with 
225
Actinium. 
225
Ac was first chelated with DOTA-Bz-NCS prior to 
being covalently conjugated to BG1. The resultant [
225
Ac]DOTA-BG1 was purified by size exclusion column before 
being used for in vivo biodistribution. 
        
  Two groups of C57BL6 mice (n = 3 per group, 5 months old, female) from Jackson 
Laboratory were injected with 300nCi of [
225
Ac]DOTA-BG1 retro-orbitally. The first group was 
sacrificed 1-hour post injection while the other group was sacrificed 72 hours post injection. 
Their blood, heart, lungs, liver, spleen, stomach, small and large intestines, kidneys, muscle, 
bone, brain and urine were collected, weighed and counted for gamma decay 24 hours post 
collection. 
 
Kidney Uptake of BG1-AlexaFluor488 
To further investigate the region-specific uptake of BG1 in the kidneys mice were treated 
with and AlexaFluor488 (AF488) labeled version of BG1. BG1 was dissolved in 0.1M phosphate 
buffer with 0.15M NaCl pH7.5 and 20% acetonitrile (v/v). AlexaFluor488 tetra fluorophenyl 
ester (AF488-TFP) in a ratio of 1 fluorophore to 2 amines was added to the reaction and mixed 
for 2 hours at room temperature. The reaction was quenched by adjusting the pH to 8.5 with 
NaOH. The reaction mixture was dialyzed in a dialysis cassette (MWCO 3.5kDa). 
Five C57BL6 mice (5 months old, female) were injected with the AlexaFluor488 
conjugated construct. After 24 hours the mice were sacrificed and their kidneys, liver, spleen 
heart and lymphatic tissues were harvested, washed in PBS and fixed overnight at 4˚C in 4% 
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paraformaldehyde. The tissues were embedding into paraffin, sectioned into 5um samples for 
immunofluorescent staining (IF). Briefly, the tissues were stained with anti-AF488 (Molecular 
Probes, cat no A-11094, 5ug/mL) and then stained with biotinylated goat anti-rabbit IgG (Vector 
Labs, cat. No. PK6101 1:200 dilution) and the nuclei of the cells were stained with DAPI. 
Images of the stained slides were taken with an Axioplan2 imaging microscope equipped with 
AxioCam MRm Camera (Zeiss, Inc) and an Inverted Leica TCS SP5 microscope (Leica 
Microsystems, Inc). 
 
In vivo Knockdown of eGFP with BG1-siRNA 
To determine if BG1 could deliver knockdown gene expression in the kidneys ten 3-
month-old mice (5 females and 5 males) over-expressing eGFP were injected with either PBS or 
BG1 and specific siRNA for eGFP (sieGFP). The PBS control group contained 1 male and 3 
females while the group that received BG1-sieGFP was composed of 3 males and 3 females. The 
mice had been genotyped by Polymerase Chain Reaction (PCR) prior to the start of the 
knockdown experiment using REDExtract-N-Amp Tissue PCR kit (Sigma Aldrich, cat. No. 
XNAT-100RXN) and GFP173-F and GFP173-R primers (all primer sequences are listed in the 
Appendix). 
Briefly, approximately 2mm of a mouse’s tail was cut and placed into an Eppendorf tube 
and stored at 4˚C until the PCR reaction could be done. To each tail sample 25uL Tissue 
Preparation Solution and 100uL Extraction solution was added and the samples incubated at 
room temperature for 10 minutes before being heated at 95˚C for 3 minutes. The samples were 
cooled and then 100uL Neutralization Solution B was added and vortexed. The volumes used for 
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each PCR reaction and thermocycler settings were set up as the shown in the table below (Table 
8). 
The PCR products were run on a 5% agarose gel stained with Gel Red Nucleic Acid Stain 
x10,000 (Biotium cat. No. 41003) and visualized on a ChemiDoc MP Imaging System with 
Image Lab software. Positive eGFP expressing samples showed a band at ~200bp. 
It was assumed that BG1 had a molecular weight of 300kDa and a stock solution of 1.5g/L = 
5um. SiRNA specific for eGFP were diluted to 20um with DNase, RNase Free water and 
annealed at by heating at 95˚C then allowing cooling to room temperature. BG1 and sieGFP 
were mixed in a 1:1 molar ratio to make a 3um solution. 
Table 8: eGFP genotyping primers and reaction 
eGFP genotyping primer sequences 
GFP173-F primer 5'-GAG CTG AAG GGC ATC GAC TTC AAG-3' 
GFP173-R primer 5'-GGA CTG GGT GCT CAG GTA GTG G-3' 
         
PCR reagents per well   PCR settings 
Reagent Volume   Step Temperature Time Cycles 
Water 4uL   Initial denaturation 94˚C 
3 
minutes 
1 
REDExtract-N-Amp 
PCR Mix 
10uL   Denaturation 94˚C 
30 
seconds 
30-35 
GFP173-F primer  
(10um stock) 
1uL   Annealing 60˚C 
45 
seconds 
GFP173-R primer 
(10um stock) 
1uL   Extension 72˚C 
45 
seconds 
Tissue extract 4uL   Final extension 72˚C 
10 
minutes 
1 
Final volume 20uL   Hold 4˚C Infinite  
 
The mice were injected retro-orbitally so that the final concentration of BG1-sieGFP was 
300nM. One injection was made each day for three consecutive days and then the fourth day the 
kidneys, liver, spleen and heart were collected for histology, qPCR and Western blot analysis. 
 For histology the tissues were fixed in 4% PFA immediately after collection and placed 
at 4°C overnight. After being fixed the tissues were stored in 70% ethanol at 4°C until they were 
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embedded in paraffin. The tissues were cut into 5um thick sections and fixed onto glass slides for 
DAPI staining. The stained slides were imaged and then regions were annotated under 20x 
magnification for pixel analysis. The total eGFP (green pixels) and DAPI stain (blue pixels) were 
counted for each annotation and the ratio of eGFP to DAPI was calculated. 
 
In vitro Knockdown of eGFP in HEK293t cells 
 To test BG1’s ability to deliver siRNA for gene silencing in vitro HEK293t cells 
overexpressing eGFP was done. The HEK293t cells were transduced as described in Chapter 3. 
The cells were plated 500k cells/well in a 6-well plate that was pretreated with poly-D-lysine and 
grown with DME media containing high glucose, non-essential amino acids 10% fetal bovine 
serum glutamine, penicillin and streptomycin at 37˚C with 5% CO2. After 2 days the cells were 
50-60% confluent and the cells were treated with either PBS, Lipofectamine RNAi MAX 
(Invitrogen) with sieGFP or BG1 with sieGFP; the siRNA used here was the same sequence used 
in the in vivo experiment. The Lipofectamine group each well was treated with 0.004mL 
Lipofectamine with 30pmol siRNA in 2mL OptiMem Reduced Serum Medium (Gibco). After 5 
hours the wells were aspirated and changed to fresh OptiMem media. The BG1 siRNA treated 
wells were treated with BG1 mixed with sieGFP in a 1:1 molar ration so that the final 
concentration would be 300nM in 2mL media. The media was not changed in the BG1 treated 
wells. Each group was seeded in triplicate and there were four technical replicates for each well 
for the Quantitative Reverse Transcriptase PCR (qRT-PCR).  
 After 24 hours the cells were harvested, and total RNA was extracted using Qiagen’s 
Rneasy Plus Mini Kit. The RNA was quantified by a Nanodrop and 100ng was used to 
synthesize cDNA using qScript cDNA Supermix (Quanta Bio). For the qPCR reaction 0.002mL 
64 
 
of the cDNA was used for each well and Perfecta Fastmix II along with primers for eGFP (FAM-
MGB labeled; Life Technologies Mr04329676) and the reference gene Human TBP (VIC/MGB 
labeled; Life Technologies 4325803) were added in multiplex. The qPCR reaction was done 
using a Bio-Rad C1000 Touch Thermocycler with an attached CFX96 Real-Time System and 
Bio-Rad CFX Manager software. The data was analyzed using Microsoft Excel using the ΔΔCq 
method (193) and plotted on GraphPad Prism 7. 
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Results 
 
Chemical Functionalization and Physical Characterization of CNC 
Raw cellulose nanocrystals from Blue Goose Biorefineries were ammonium 
functionalized using three different chemistries to produce several derivatives. The CNC samples 
were supplied as a slurry: BGB Natural (7.4% w/v; lot# ANN05-004) and BGB Ultra (8.0% w/v; 
lot# AUU06-006). The goal of the chemical modifications was to increase the water solubility of 
the CNC and addition of ammonium groups on the surface of the CNC for drug delivery. 
 
Figure 26: Cellulose nanocrystal. Cellulose is a polymer of glucose connected by β-1,4-glycosidic bonds. 
Hundreds of glucose units can be linked in a single cellulose chain this way. Lateral association of the cellulose 
chains through hydrogen bonding and van der Waals interactions give CNCs their great mechanical properties. 
 
Four products were produced from the two samples of pristine CNC samples (Figure 27). 
BG1 was produced from BGB Natural first by iodination at the secondary alcohols to break 
intermolecular hydrogen bonds between cellulose chains. The iodinated product was then reacted 
with the epoxide epichlorohydrin (ECH) and the diamine 2,2′-(Ethylenedioxy)bis(ethylamine) 
(EBEA). The product showed increased water solubility compared to the pristine CNC. Of the 4 
different products synthesized cellulose nanocrystal, BG1 was the most studied (Table 9). Its 
physical properties, as well as biodistribution in vivo and the possibility to utilize BG1 in RNAi 
were investigated. 
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Figure 27: Reactions to produce BG1, BG2 and BG3. BG1 was produced by first iodinating the secondary 
alcohols of pristine CNC followed by amination of the primary alcohols with diamine (EBEA). BG2 was produced 
by acid oxidation of the primary alcohols and then aminating with EBEA. BG3 was produced by directly aminating 
the carboxylic groups present on the pristine CNC. 
 
BG2 and BG2a were products of oxidizing the primary alcohols of the glucose units to 
carboxylic groups that could then be conjugated with EBEA. BGB Ultra was oxidized with nitric 
acid while being sonicated to disperse the CNC. After thoroughly washing away the nitric acid, 
the resultant oxidized CNC was reacted with EDC followed by EBEA. The product was called 
BG2. An aliquot of BG2 underwent a second reaction with EDC and EBEA to further increase 
the water solubility and ammonium content. However, there was no increase in the ammonium 
content of BG2a from BG2. This may be due to inaccessibility of the remaining carboxylic 
groups or, less likely, saturation of all the carboxylic acid groups from the first reaction. Without 
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an assay to determine the carboxylic content it cannot be assessed whether all carboxylic groups 
have been chemically functionalized. Of the CNC derivatives BG2 and BG2a appear to be the 
least soluble, forming a floc in water readily while the others are well dispersed. 
As mentioned earlier, the process of generating CNC from plant material carboxylic 
and/or sulfonyl groups are introduced into the CNC during acid hydrolysis. BG3 was synthesized 
by exploiting the preexisting carboxylic groups of the CNC. BGB was reacted with EDC 
followed by EBEA to yield the ammonium functionalized BG3. This method was similar to 
generation of BG2, forgoing the oxidation of the alcohols. 
Table 9: Physical properties of pristine CNC and their derivatives. Carboxylic group content data was provided 
by Blue Goose Biorefineries material specification sheet. 
 BGB Natural BGB Ultra BG1 BG2 BG2a BG3 
Starting material - - BGB Natural BGB Ultra 
Estimated -COOH groups (mmol/kg) 140 292 N/D N/D 
Ammonium content (mmol/g) 0.031 0.01 0.285 0.058 0.058 0.314 
Size (by TEM) (nm) 195.7 by 13.9 N/D 162.4 by 11.20 N/D N/D N/D 
Size (by AFM) (nm) 156.6 by 9.81 N/D 164.0 by 10.52 N/D N/D N/D 
Zeta potential (mV) 
-27.60 
± 4.33 
-17.50 
± 1.59 
-20.37 
± 0.03 
-17.23 
± 1.10 
N/D 
-20.70 
± 1.54 
 
The physical properties of the cellulose nanocrystals were analyzed by size exclusion 
HPLC, Sarin assay to assess ammonium content and Dynamic Light Scattering. There are 
several vital pieces of information that are still missing in characterizing the fCNC such as the 
molecular weight, the degree of polymerization of glucose units in a CNC molecule and the 
carboxylic/sulphonyl content. 
By themselves CNCs have negligible UV/Vis absorbance. A standard curve for the 
absorbance and concentration of BG was created by measuring the absorbance of light at 600nm 
in water with serial dilutions of the unmodified nanomaterial (Figure 28). To ameliorate the 
issue of having no native absorbance peak in the UV/Vis spectrum, BG1 was conjugated with the 
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fluorophore AlexaFluor488 (AF488) to produce BG1-AF488 for HPLC analysis. On a C18 
reverse phase HPLC column the BG1-AF488 does not appear to chromatograph when using 
0.02M ammonium acetate, 0.15M sodium chloride 0.02% sodium azide and acetonitrile as 
mobile phases. There was no signal detected in the fluorescence emission spectrum of AF488 
(Data not shown). This is possibly due to the low solubility of BG1-AF488 in aqueous solutions 
and the fCNC forming aggregates. 
 
Figure 28: Standard curve of CNC absorbance at 600nm. Serial dilutions of a 10mg/mL solution of CNC were 
made with water and their absorbance at 600nm were measured in triplicate. 
  
When analyzed by size exclusion HPLC on the other hand, BG1-AF488 behaves like a 
small molecule eluting late (41 minutes) (Figure 29). Like functionalized carbon nanotubes the 
fibrillar nature of the cellulose nanocrystals does not behave like globular proteins when 
analyzed by a size exclusion column. This behavior was expected as the fCNC have similar size 
and molecular weights to other fCNT we have worked with. When compared with molecules like 
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mouse IgG (150kDa) and AlexaFluor 488 (650Da), BG1-AF488 behaves more like a small 
molecule than the larger globular protein. 
 
Figure 29: Size exclusion HPLC of BG1-AF488. BG1-AF488 (black trace on chromatograms) displays elution 
behavior like small molecules. CNC do not absorb UV/Vis or fluoresce, requiring conjugation with a fluorophore 
AlexaFluor488 (AF488).  Standards were also run on the same column to estimate the molecular weight of BG1. 
Mouse IgG conjugated with DyLight650 (150kDa; red trace) and AlexaFluor488 (650Da; green trace). 
 
To assay the ammonium content of the cellulose nanocrystals the Sarin assay was 
utilized. The assay produces a blue color that can be detected on a UV/Vis spectrophotometer at 
570nm when ninhydrin reacts with free primary amines. The ammonium functionalized products 
and starting CNC were assayed and summarized in table (Table 9). The carboxylic content of the 
pristine CNC was assayed by the vendor Blue Goose Biorefineries. BGB Ultra contains more 
than double the carboxylic groups of BGB Natural. This may have helped in the synthesis of 
BG3 which relied on utilizing –COOH groups as the linker for EDC and then the diamine 
EBEA.  
Of the four functionalized CNC products BG3 has the highest ammonium content 
followed by BG1 and then BG2 and BG2a. BG2 and BG2a have the lowest values, being only 
marginally higher than the starting material BGB Ultra (0.058mmol/g and 0.010mmol/g, 
respectively). This suggests that the oxidation of the primary amines of the glucose units in 
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cellulose was not efficient possibly due to strong intermolecular hydrogen bonding between 
cellulose chains. Furthermore, BG2a and BG2 had similar ammonium content based on the Sarin 
assay (0.058mmol/g) indicating that the second amination reaction with EDC and EBEA did not 
further increase the ammonium content of BG2. The first amination reaction most likely 
saturated all the –COOH reaction sites. 
Table 10: Dynamic Light Scattering of CNC dispersed in water. 
Sample Z-average (r-nm) PdI 
BG Natural 46.08 0.202 
BG Ultra 47.03 0.222 
BG1 288.63 0.463 
BG2 306.77 0.640 
BG3 61.67 0.166 
 
Size distribution and zeta potential of the CNC were analyzed. Dynamic light Scattering 
(DLS) was used to determine the size distribution of the pristine CNC and functionalized 
products. DLS data showed that the hydrodynamic radii of the CNC were smaller than expected 
(Table 10). This may have been due in part to the fibrillar nature of the CNC nanoparticles 
tumbling in solution. DLS measures the mean hydrodynamic radius of a spherical molecule and 
fibrillar molecules may obfuscate the measurement with their high aspect ratios. Their 
hydrodynamic radii should be more ovoid-like than spherical. Additionally, during data 
collection the DLS instrument detected particles settling in the solution which may have been 
CNC that due to poor dispersion of the CNC. Unexpectedly with respect to the ammonium 
modified CNC, BG3 has the smallest hydrodynamic radius which is several times smaller than 
BG1 and BG2. In addition, its trace was the most uniform showing a single bell-shaped curve 
while the other two showed several peaks. Perhaps this was attributed to BG3’s improved water 
solubility compared to the others.  
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Zeta potential was measured for several of the samples (Table 11). At neutral and high 
pH all the samples had negative zeta potentials. Of the samples BG3 had the most negative value 
at neutral pH in terms of magnitude, suggesting that it is the most disperse in water of the 
derivatives generated. This would agree with the DLS data that BG3 was the most disperse of the 
three functionalized CNC. At low pH the unmodified BGB Natural and BGB Ultra maintain 
negative zeta potentials but much smaller in magnitude than at higher pH. On the other hand, 
BG1 and BG3 show marginally positive values, indicating the protonation and presence of 
positively charged amines on the surface of BG1 and BG3 (194). 
Table 11: Zeta potentials of CNC and their products 
Sample pH 1 pH 3 pH 7 pH 9 
BGB Natural (7.4% w/w) +0.182 ± 1.61 -2.86 ± 0.204 -33.7 ± 1.49 -18 ± 1.49 
BG1 +3.88 ± 0.954 +1.25 ± 0.158 -22.2 ± 1.23 -21 ± 2.31 
BGB Ultra (8.0% w/w) N/D -5.24 ± 0.367 -23.1 ± 0.961 -18.7 ± 1.41 
BG3 N/D +0.538 ± 0.641 -45.4 ± 2.85 -27 ± 1.19 
 
Fourier Transformation Infrared Spectroscopy (FTIR) data were taken of pristine CNC 
and BG1 (Figure 30). However, the presence of ammonium groups was not easily apparent in 
the spectra; the expected amine N-H stretch at ~3500 cm
-1
 was not observed, partially due to the 
strong –OH peak present in that region. The amine stretches are present in the diamine EBEA 
spectrum at 3371 cm
-1 
and 1596 cm
-1
. The spectra of pristine and fCNC show characteristic D-
glycosyl peak at 892cm
-1
 (194) as well as peaks at 1032 cm
-1
 and 1160 cm
-1
 corresponding to C-
O and C-O-C stretches between glucose units, respectively. 
Titrations of the CNC were completed to estimate the pK values the ammonium groups 
present. The dilute solutions of BG Natural, BG Ultra, BG1 or BG3 were first titrated with 0.1N 
NaOH to fully deprotonate the ammonium and carboxylic functional groups followed by a 
reverse titration with 0.1N HCL (see Appendix Figure 55). Like the FTIR results the presence of 
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the ammonium groups was not clear. In the four titrations they all show a pKa value of ~6.3 and 
another pKa at ~3.  
 
Figure 30: FTIR spectra of pristine CNC, BG1 and diamine (EBEA). The diamine EBEA (blue trace) shows a 
weak N-H amine stretch ~3376cm
-1
, amide 1 peak at 1596 cm
-1
. Pristine CNC (BGB Natural; red trace) and BG1 
(fCNC; black trace) do not show these characteristic peaks for an amine group. Pristine CNC and BG1 display 
characteristic –OH groups ~ 3400 cm-1 and D-glycosyl peak at 892 cm-1. 
 
In vivo Tissue Uptake of [
225
Ac]DOTA-BG1 
We have previously worked with single-walled carbon nanotubes which have shown 
quick blood clearance and tissue-specific uptake in the kidneys, liver and spleen. It was possible 
that the functionalized CNC would have similar properties. The in vivo blood clearance and 
tissue uptake of BG1 was explored by biodistribution of 
225
Actinium labeled BG1 in mice. Six 
female C57BL6 mice, 5 months old were injected with [
225
Ac]DOTA-BG1 and then three mice 
were sacrificed 1-hour post injection while the remaining three were sacrificed 72 hours post 
injection (Figure 31). 
After 1 hour, majority of the radioactivity was detected in the urine indicating fast blood 
clearance akin to fCNTs. The radiolabeled BG1, however did not completely clear the blood as 
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there was still approximately 18.2% activity present. Also, at this time point the liver had taken 
up 23.45% of the [
225
Ac]DOTA-BG1. By 72 hours post injection nearly all BG1 had cleared 
from the blood of the animals with only less than 2% remaining. The kidneys retained 14.56% 
activity while the next highest tissue uptake was in the liver at 6.07% and the spleen at 7.68%.  
 
 
Figure 31: Biodistribution of radiotracer labeled BG1 in mice. Mice were injected with 
225
Ac radiolabeled BG1 
and sacrificed either 1-hour or 72-hour post injection. After 1-hour most of the injected radioactivity was excreted 
while ~18% remained in the blood while the kidneys retain >20% and the lungs ~10%. After 72-hours the activity 
cleared from the blood (<1% activity) while the kidneys still contained ~15% activity and the spleen and liver <8% 
each. The 1-hour urine activity bar is cut off in the y-axis due to its high value. 
 
The biodistribution results show the fast blood clearance of BG1 in vivo and uptake of the 
nanoparticle was primarily in the kidneys. Fibrillar molecules such as carbon nanotubes and 
cellulose nanocrystals can quickly clear the blood through the kidneys due to their high aspect 
ratio allowing them to align with blood flow through the glomerulus of the kidneys to be 
collected in the bladder with the urine. Also, of note is lack of cytotoxicity of the CNC. None of 
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the animals appeared have visible health issues after the 72-hour time point and there was no 
uptake in the lungs that could suggest possible pulmonary toxicity caused by the CNCs. 
 
Figure 32: In vivo uptake of BG1-AF488.  Mice were administered fluorophore labeled BG1 (BG1-AF488 Twenty 
hours post injection the mice were sacrificed, and their heart, liver, kidney and spleen were taken for paraffin fixing 
and processing. Immunofluorescence images of 5um sections were stained with anti-eGFP (green) and nuclei were 
stained with DAPI (blue). The heart was used as a negative control while the liver and spleen show limited staining 
for BG1-AF488. The kidney cortex shows substantial staining for BG1-AF488. 
 
To further inspect region specific uptake of BG1 in the kidneys and liver, mice were 
treated with AlexaFluor488 labeled BG1. Five female 5-month-old C57BL6 mice were given a 
single injection of BG1-AF488 and euthanized 20 hours post injection, their tissues harvested 
and fixed for sectioning and staining. Based on biodistribution of radiolabeled BG1, it did not 
accumulate in the heart allowing it to be a negative control for this experiment. The cell nuclei of 
the tissues were stained with DAPI while BG1-AF488 was targeted with an anti-AlexaFluor488 
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antibody and imaged by immunofluorescence (Figure 32). Staining for BG1-AF488 indicated 
that it was present in the kidney cortex, liver and spleen and confirmed to be absent in the heart. 
The heart showed only DAPI staining in the nuclei of the cells whiles the kidneys showed 
significant green fluorescence from the BG1-AF488. In the liver and spleen there was nominal 
AF488 fluorescence. 
 
Gene Knockdown with BG1+siRNA 
 To test the possibility of using BG1 as an RNA interference delivery vehicle, eGFP 
expressing transgenic mice were treated with BG1 carrying siRNA. Mice were first genotyped 
for being positive for the expression of eGFP by PCR. The PCR reaction was done using 
amplifying a fragment of eGFP’s gene with a set of primers (GFP173-F and GFP173-R). Mice 
positive for eGFP would show an intense 200bp band on a 5% agarose gel. For the knockdown 
experiment only the mice strongly expressing eGFP were used. 
Mice were injected retro-orbitally with BG1-siRNA specific for eGFP for three 
consecutive days with BG1-siRNA or PBS. On the fourth day the mice were sacrificed and their 
kidneys for IF staining. In the PBS control mice kidneys there was systemic eGFP expression 
throughout the kidneys. However, in the kidneys of mice treated with fCNT+sieGFP there was 
less expression of eGFP present in the medulla (Figure 33). This suggests that BG1can be used 
for gene knockdown specifically in the medulla of kidneys. 
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Figure 33: In vivo knockdown of eGFP with BG1 showing kidney cortex and medulla. Mice were treated with 
either PBS (top row) or BG1+siRNA specific for eGFP (bottom row). The kidneys from the PBS treated mice show 
homogenous eGFP expression throughout the kidneys. Kidneys from mice treated with BG1+siRNA show 
decreased expression in the medulla. The cortex and medulla regions are labelled in red; the scalebar in white 
represents 200um. 
 
HEK293t cells that were previously transduced to overexpress eGFP (see Chapter 3 for 
procedures) were used in an in vitro gene silencing experiment. The cells were either treated with 
PBS (labeled Untreated), commercially available Lipofectamine RNAi Max with sieGFP 
(Lipo+sieGFP) as a positive gene knockdown control or BG1 with sieGFP (Figure 34). When 
treated with Lipo+sieGFP there was only a marginal decrease in eGFP mRNA transcripts 
compared to the control group. The BG1+sieGFP group showed a greater decrease in eGFP 
mRNA but there were two points, one high expressing and one low expressing. This data is not 
strongly convincing that there was gene silencing in these transduced cells but did show the 
expected trend .  
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Figure 34: In vitro knockdown of eGFP in HEK293t cells by BG1+sieGFP. HEK293t cells were transduced to 
overexpress eGFP and assayed by qPCR (left). Transduced cells were treated with PBS (labeled Untreated), 
Lipofectamine with siRNA targeting eGFP (Lipo+sieGFP) or BG1 with specific siRNA (BG1+sieGFP). 
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Discussion 
 
The purpose of this work was to provide an alternative fibrillar nanoparticle to fCNT for 
RNAi delivery. The hypothesis was that the ability of carbon nanotubes to filter through the 
glomerulus of the kidney and be excreted was due to its rigid fibrillar nature; therefore, other 
nanomaterial with similarly high aspect ratios should perform comparably. Cellulose 
nanocrystals (CNC) were chosen as a potential substitute to carbon nanotubes due to their rigid 
polymeric structure and affordability.  
While other groups have previously ammonium functionalized and characterized CNC 
using a variety of chemistries (194, 195), this work has been the first to show in vitro and in vivo 
delivery of RNAi by fCNC. Delivery of BG1-siRNA showed in vivo knockdown of eGFP in the 
kidneys of mice. Transgenic mice expressing eGFP were treated with BG1-sieGFP and their 
kidneys, liver and hearts were collected for fluorescence imaging (IF) and qPCR. In qPCR the 
relative quantity of eGFP mRNA in the kidneys decreased compared to controls and IF 
confirmed this finding. However, the location of where eGFP protein expression decreased was 
not expected. Gene knockdown with fCNT-siRNA occurred predominantly in the cortex of the 
kidney, while the knockdown of eGFP with fCNC-siRNA appeared mostly in the medulla of the 
kidneys. This suggests a possible different uptake mechanism for the fCNC than the fCNT and 
release of the siRNA cargo to fCNT. We suspected that fCNT uptake in the cortex was due 
receptor mediated endocytosis by megalin and stabilin. Uptake of the fCNC may be because of 
another receptor or mechanism entirely. These results confirmed that cellulose nanocrystals can 
indeed be a potential alternative in delivering RNAi to the kidneys.  Furthermore, the location of 
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gene knockdown in the kidney medulla also suggests that different uptake receptors are at play 
here than with the fCNT. 
An additional note is the initial uptake of the radiolabeled BG1 in the lungs at 1-hour post 
injection but then at 72-hours there is relatively no activity present in the lungs. Pulmonary 
uptake of CNC and other fibrillar nanoparticles or asbestos like particles is a major concern in 
development of nanoparticle drug delivery systems (187-189). Currently there has not been 
sufficient long-term research in how nanoparticles such as CNT may affect the lungs or other 
tissues, never the less, fibrillar nanoparticles have been categorized similarly to asbestos as a 
cautionary measure. Further testing is required to assess their long term affects. 
As shown in this work with the CNC, VACNT and single wall CNT and previous 
publications by our group there is virtually no uptake of the functionalized nanoparticles in the 
lungs after 24-hours. Correspondingly, with the single-walled CNT and multi-walled VACNT 
there is no uptake in the lungs, brain or heart. This may be due to the water-soluble nature of the 
functionalized nanoparticles compared to the raw nanoparticles which are highly hydrophobic 
and aggregate readily. These different properties may give rise to different uptake and 
pharmacokinetic profiles for the nanoparticles. 
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Chapter 3: Sodium dependent GLucose co-
Transporter 2 (SGLT2) Knockdown Mediated by 
Functionalized Carbon Nanotubes 
 
Introduction 
  In this chapter silencing of a glucose transporter, SGLT2 mediated by single-walled 
carbon nanotubes is described. Previous work by our group has shown that fCNT are capable of 
robust gene silencing in the kidneys. By targeting SGLT2 with specific siRNA delivered by 
fCNT renal reabsorption of glucose is a prevented thus decreasing plasma glucose level. Our 
hypothesis is that fCNT carrying siRNA targeting this kidney specific transporter may alleviate 
hyperglycemia in Type 2 Diabetes. 
Sodium dependent GLucose co-transporter 2 (protein symbol for humans SGLT2 and 
gene symbol for humans SLC5A2) is a member of the solute carrier symporter family 5 (SLC5) 
of transporters. Another member of the same gene family, SGLT1 was first cloned by Wright et 
al. in the 1990’s from the intestines of porcines and soon after SGLT2 was cloned from bovines 
(196-205). The two sugar transporters share ~76% amino acid sequence identity (196). However, 
the two serve very distinct roles (Table 12). SGLT2 has a low affinity for glucose but a high 
transport capacity allowing it to recover the bulk of glucose passing through the kidneys whereas 
SGLT1 has a high affinity but low capacity to collect any remaining glucose present in the 
extracellular fluid in the kidneys. The protein expression profiles of the two are also significantly 
different; SGLT1 is highly expressed in the intestines, heart and skeletal muscles, SGLT2 is 
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highly expressed in the kidneys. SGLT transporters are dependent on the presence of sodium 
ions to drive import of glucose into cells against glucose’s concentration gradient (135). It is 
believed that >90% of the glucose entering the Proximal Tubules is reabsorbed by SGLT2 while 
the remaining 10% is taken up by SGLT1, thus preventing loss of glucose into the urine. 
SGLT2 and SGLT1 are both members of the SLC5 gene family of solute transporters but 
differ in several significant ways. SGLT2 only transports the sugar glucose with a low binding 
affinity and in a ratio of 1:1 with sodium ions. SGLT1 on the other hand has a high affinity for 
glucose and galactose and requires two sodium ions per sugar molecule transported (206). Below 
is a table contrasting the two transporters (199, 207, 207-209): 
Table 12: Comparison of Sodium dependent GLucose co-transporter 1/2. Here the murine form of glucose 
transporters are abbreviated Sglt for the protein and Slc5a for the gene to differentiate it from the human forms. 
 SGLT2 SGLT1 
Amino acid length, 
molecular weight 
672 amino acids, 73kDa 73kDa 
NCBI accession number 
(protein) 
Human SGLT2 : NP_003032 
Mouse Sglt2: NP_573517 
Human SGLT1: NP_000334 
Mouse Sglt1: NP_062784 
Gene symbol 
SLC5A2 for humans 
Slc5a2 for mice 
SLC5A1for humans 
Slc5a1 for mice 
NCBI accession number 
(mRNA) 
Human: NM_003041 
Mouse: NM_133254 
Human: NM_000343 
Mouse: NM_019810 
Locations of protein 
expression 
Kidney Proximal Tubules (early 
section) 
Intestines, Skeletal muscles, Heart 
and Kidney Proximal Tubules (late 
section) 
Substrates Glucose and Na+ ions Glucose, Galactose and Na+ ions 
Glucose reabsorption in 
nephron 
~90% ~10% 
Glucose affinity (Km) N/D 0.4mM 
2-Deoxyglucose Affinity 
(Km) 
10mM 0.2mM 
Sodium : Glucose 
stoichiometry 
1:1 2:1 
Diseases caused by 
mutations 
Familial Renal Glucosuria (FRG) 
Glucose-Galactose Malabsorption 
(GGM) 
 
SGLT2 is a complex and confounding multi-pass transmembrane protein found in the 
kidney cortex; more specifically the early section of the Proximal Convoluted Tubules (PCT) 
(Figure 35) (135). There has been great debate on whether SGLT2 is expressed in other tissues 
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as well. Other groups using different techniques searched for expression of SGLT2 in varying 
tissues found conflicting results (142, 208). The consensus has been that SGLT2 is expressed 
predominantly in the kidney cortex and other regions are still disputed.  
 
Figure 35: SGLT2 mRNA expression in human tissues.  SGLT2 mRNA is present exclusively to the kidney 
cortex and to a minor extent the kidney medulla. GAPDH was used as a reference gene to normalize the gene 
expression data. Image from Chen Diabetes Ther 2010. 
 
Several groups have found an increased expression of SGLT2 in diabetic animal models 
and patients while others have contradicted these findings (210-219). Rahmoune showed that 
SGLT2 expression was increased in cultured human excreted Proximal Tubule endothelial cells 
derived from diabetic patients (217). Conversely, in streptozotocin induced diabetic mice (214) 
saw a decrease in Sglt2 expression. Finally, to add to the mystification of SGLT2 there has been 
reported differences in expression of SLGT2 between male and female mice and rats but not 
humans (220). 
Expression of human SGLT2 in transfected cell lines or exogenous expression systems is 
an exorbitantly challenging task making biophysical studies very limited for such a biologically 
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relevant target. One reason why it is difficult to study SGLT2 in vitro expression is proper 
folding and function of the transporter. The co-expression of a membrane associated protein, 
Map17 has been implicated as a functional activator of SGLT2 present in a cell but does not 
increase the expression levels of SGLT2 within the cell (221-223). Additionally, Friendlander et 
al. described the requirement of vimentin in cultured primary cells derived from mice was 
required for proper function of the PT cells (224). 
 
Figure 36: Topology of human SGLT1. SGLT1 is an integral membrane protein with 14 transmembrane domains. 
Both the N- and C- termini are located in the extracellular side of the cell. There is an N-linked glycosylation site 
Asn248. The transmembrane domains of SGLT1 are labeled TM1-TM14 below the diagram. Image from Wright 
Physiol. Reviews 2011.  
 
Biophysical and protein characterization work done on SGLT2 has been through in vitro 
overexpression systems. Although it is a transmembrane protein its mRNA sequence (NCBI 
accession number NM_003041 for humans SLC5A2 mRNA) lacks a signal peptide to transport 
the ribosome synthesizing SGLT2 to bring the nascent peptide sequence to the Endoplasmic 
Reticulum for proper synthesis, folding and modifications. There is currently no crystal structure 
available for SGLT2, however based on the closely related crystal structure of Sglt1 from V. 
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parahaemolyticus (225) the transporter contains 14 predicted transmembrane helices as well as 
two asparagine glycosylation sites on the extracellular side of the transporter (at Asn248) 
(Figure 36) (205, 226-228). It has been commented that SGLT1 is easier to express in a foreign 
expression system and much of the biophysical information of SGLT2 has been inferred from 
SGLT1. 
 The kidney of a healthy adult man can produce 180 liters of primary urine each day, of 
which there will be virtually zero glucose present when excreted (94). This is due to the glucose 
transporters, such as SGLT2, SGLT1 and others present in the kidneys that reabsorb glucose and 
send it back into the bloodstream. In a healthy adult this recovers 180g glucose per day (135, 
229). SGLT2 is present in the early sections (S1 and S2) of the Proximal Convoluted Tubules 
(PCT) of the kidneys while SGLT1 is present in the later parts (S3) of the PCT (Figure 37) 
(135). While SGLT2 can only transport one molecule of glucose for each sodium ion taken into 
the cell, SGLT1 can transport one molecule of glucose or galactose at the cost of importing two 
sodium ions (229).  
 
Figure 37: Diagram of a renal nephron. SGLT2 is expressed only in the early S1 section of the nephron and can 
reabsorb ~90% of the glucose that passes through while SGLT1 is expressed in the later S3 region reabsorbing the 
remaining 10%. Together they prevent the excretion of glucose in a healthy person. Image from Bailey. Cell 2010. 
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To prevent a buildup of glucose in the polarized cells of PTC, the SGLT co-transporters 
are expressed on the luminal surface of the PCT cells while members of the GLUT family of 
sugar transporters are expressed on the basolateral side (Figure 38). SGLT2 will import glucose 
from the luminal side of the PTC into the cell against its concentration gradient and then a GLUT 
transporter will export glucose back into the blood (135, 229). To drive this transport against its 
concentration gradient sodium ions must be co-transported into the cell by SGLT2. 
 
Figure 38: Diagram of a Proximal Tubule cell. The cell is polarized with the side facing the lumen of the 
Proximal Tubule (left side in image) expressing the brush border and transport/endocytosis proteins to reabsorb 
metabolites while the basolateral side (right side) faces the bloodstream. As fluid passes through the Proximal 
Tubule transporters like SGLT2 will import a molecule of glucose up its concentration gradient by co-transporting 
sodium down its concentration gradient into the cell. Once in the cell the glucose can be released back into the 
bloodstream by GLUT transporters while the sodium concentration of the cell is maintained by a sodium/potassium 
pump. Image from Bakris. Kidney International. 2009. 
 
The safety of SGLT2 inhibition/loss of function has been shown in humans with loss of 
the gene’s function. In people with mutations in the gene encoding SGLT2 (SLC5A2) the protein 
becomes nonfunctional and leads to the disease Familial Renal Glucosuria (FRG) (198, 201, 230, 
231). The major side effects experienced by FRG patients are glucosuria and increased risk of 
urinary tract infections; cases of hypoglycemia are rare in these patients. Strangely enough, the 
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daily amount of glucose lost from urinary glucose excretion varies widely from patient to patient 
indicating that there may be compensatory mechanisms to reabsorb glucose in FRG patients.  
Akin to FRG patients, Diabetic mice with Slc5a2 knocked out displayed glucosuria and 
increased urinary tract infections but hypoglycemia cases were not common. Sglt2 knockout 
mice also showed several positive side effects that may improve the Diabetic condition including 
loss of weight and lowered blood pressure (232-234). Weight loss was attributed to changes from 
using glucose and other carbohydrates as the main energy source to lipid oxidation. Lowered 
blood pressure was seen as result of increased urination and loss of solutes. The major negative 
side effects of SGLT2 loss has been increased cases of urinary tract infections as expected with 
the increased glucose content in the urine (135).  
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Materials and Methods 
 
Chemical Functionalization of Carbon Molybdenum Catalysis (CoMoCat) Single-walled 
Carbon Nanotubes 
Single-walled carbon nanotubes produced by Carbon monoxide Molybdenum Catalysis 
(CoMoCat) were chemically functionalized to contain ammonium groups on their surface. The 
pristine nanotubes were purchased from Sigma Aldrich (cat# 704113-16) and were produced in a 
similar reaction to the VACNTs as previously mentioned in Chapter 1. Briefly 1g pristine CNT 
was reacted in 500mL DMF for 5 days at 130˚C. Each day 0.5g PFA and 1g Boc-Glycine were 
added to the reaction. After the reaction the mother liquor containing the ammonium 
functionalized CNT were collected, purified and the Boc protection group was removed in the 
same procedure as previously. The Boc deprotected product was further purified by C18 Sep-Pak 
and eluted in 50% acetonitrile in water. The acetonitrile was evaporated, and the solution was 
dialyzed against water in a 70mL capacity dialysis cassette (MWCO 3.5kDa). 
 
Physical Characterization of fCNT 
The physical properties of the CoMoCat fCNT were assayed by HPLC, Sarin assay and 
siRNA titration and radiolabeled biodistribution in vivo. To determine the chemical purity of the 
fCNT 20ug fCNT were injected into a HPLC system with a C18 reverse phase column using the 
same systems as previously described and eluted with a mixture of 20mM sodium acetate, 
150mM sodium chloride and 0.2% sodium azide with increasing concentration of acetonitrile. 
The fCNT were also run on the same HPLC system with an inline gel filtration column 
(Superdex 200) with 20mM sodium acetate, 150mM sodium chloride and 0.2% sodium azide as 
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the mobile phase. The Sarin assay was conducted to determine the concentration of amine groups 
per gram of fCNT. The procedure is the same as in previous chapters. 
To assess the pharmacokinetic profile of the CoMoCat fCNT they were radiolabeled with 
Indium-111 and injected into mice. Three 13-month-old female Balb/CJ mice were injected with 
50uL (containing 2uCi of activity). After 2 hours the mice were sacrificed and their blood, heart, 
kidneys, lung, spleen, liver, stomach, large and small intestines, muscles bone, urine, ovaries and 
salivary glands were collected, weighed and counted for radioactivity. The activity in the tissues 
was corrected with a 10uL standard of Indium-111 that was also counted at the same time the 
tissues were. 
The ability to bind siRNA with the fCNT was assessed by titration of the fCNT with 
Cy3-labeled siRNA. The titration procedure and analysis was previously described in another 
section Chapter 1. The siRNA sequence used was a Cy3 labeled siRNA for mouse Sglt2 and 
sieGFP the titration was done in a solution that was 0.5mM Na2HPO4, 10mM KH2PO4 and 
137mM NaCl pH5.5 and in 10mM Na2HPO4, 2mM KH2PO4 and 137mM NaCl pH7.4. All 
siRNA sequences are listed in the Appendix (Table 18). 
 
Identifying an In vitro Model for SGLT2 
Several human primary kidney cells and cancer cell lines were tested for the expression 
of human SGLT2 protein and mRNA. Primary human kidney cells were purchased from Lifeline 
Cell Technology, human renal cortical (part number FC-0012 lot 00296) and human renal 
medullary cells (part number FC-0018 lot 0032) were grown in their proprietary media RenaLife 
media kit supplemented with LifeFactors (LS-1048). Cancer cell lines examined were HEK293t, 
HK-2, Meso37, Jurkat, and SW480. 
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Protein expression of SGLT2 was assayed by Western blot in the previously mentioned 
cells. Cells grown until ~80% confluence, washed three times with ice cold PBS buffer and lysed 
in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% Sodium Dodecyl 
Sulfate and 50mM Tris-HCl pH8) containing protease inhibitor cocktail (Pierce Tablets catalog# 
88665). The cell lysate was centrifuged at 16000x RCF and the supernatant was collected for 
protein quantification using DC protein assay (BioRad catalog# 500-0116) with a standard curve 
of Bovine Serum Albumin (BSA). Protein samples (20ug total protein) were mixed with 4x 
Laemmli buffer and heated at 95C for 5 minutes before being loaded onto a 4-15% BioRad 
MiniProtean TGX gel (catalog# 456-1084) and electrophoresed at 150 Volts for 45 minutes. One 
lane of the gel was loaded with BioRad Precision Plus Protein Standard WesternC (cat# 161-
0376). 
After running the gels were transferred onto nitrocellulose blots, washed with 25mM 
Tris, 0.15M NaCl, containing 0.02% Tween 20 pH 7.5 (TBST) three times before being blocked 
with TBST with 5% milk at room temperature for one hour. After blocking the blots were 
stained with the primary antibody (1:1000 dilution) overnight in TBST containing 2% BSA at 
4C. All primary antibodies for SGLT2 are listed in the appendix. The next day the blot was 
washed three times with TBST for 5 minutes and then stained with a goat anti-mouse secondary 
antibody conjugated to Horseradish Peroxidase (HRP) (1:5000 dilution)(Santa Cruz 
Biotechnology sc-2030) in TBST for 1 hour at room temperature. After staining with the 
secondary antibody, the blots were washed three times with TBST to remove non-specific 
binding before imaging with SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher 
catalog# 34087) and BioRad ChemiDoc MP Imaging system. 
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To determine the expression of SGLT2 mRNA in the cells Quantitative Real Time PCR 
was utilized. Cells were grown in triplicate on 6-well plates to 80% confluency before being 
washed three times with ice cold PBS and counted. One million cells were lysed with RNeasy 
RNA Extraction kit (Qiagen 74134) and the eluted in RNase free water. The total RNA 
concentration was measured on a nanodrop and cDNA was synthesized using Quanta qScript 
cDNA Supermix (Quanta 95048) with 1ug of total RNA with a BioRad C1000 Touch Thermal 
Cycler. Primer and probe sets used are listed in the appendix. 
After cDNA synthesis the qPCR was done using Quanta Fastmix II Supermix (VWR 
97065) with three technical replicates for each sample and 2uL cDNA for each replicate. To each 
well the primer/probe sets for SLC5A2 along with Tata Box binding Protein (TBP) as a reference 
gene were added in multiplex. The probe for SLC5A2 was labeled with the fluorophore FAM 
while the TBP probe was labeled with Vic.  The qPCR reaction done in a BioRad CFX96 Real 
time system and BioRad C1000 Touch Thermal Cycler. The thermocycler temperature and time 
programs are summarized below. The data was analyzed using the ΔΔCq method. 
 
SGLT2 Overexpression in HEK293t cells 
A human SGLT2 expression vector from GeneCopoeia (EX-C0047-Lv105-B) or a 
control Enhanced Green Fluorescent Protein (eGFP) expressing vector (EX-EGFP-Lv105-B) 
was transduced into the HEK293t cells (Figure 39). The expression vectors were supplied as 
bacterial glycerol stocks. The bacteria were cultured in TB media and plasmid DNA was purified 
by PureLink HiPure Plasmid Filter DNA Purification kits (ThermoFisher Scientific K210016) 
were done to increase the quantity of plasmid DNA. The insert for SGLT2 ORF was confirmed 
by sequencing using the following primers (Table 13). 
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Figure 39: Backbone pReceiver-Lv105 vector used for SGLT2 and eGFP expression. The Lenti viral vector 
contains a CMV promoter for expression of the gene of interest, puromycin for selection in transduced cells and an 
ampicillin resistance for selection in bacteria. Image from Genecopoeia 
 
Table 13: Primers used for sequencing human SGLT2 
Name Sequence 
CMV promoter  
forward primer 
Universal primer provided by  
MSKCC sequencing core 
Primer 1 5’-GTTACGCCTTCCACGAGG-3’ 
Primer 2 5’-TTACATCCAGGCAGTCTCTA-3’ 
Primer 3 5’-GTGGAATGAGCAGAGGTG-3’ 
Primer 4 5’-CAATCCTGCTGACATCCTAG-3’ 
 
To transduce HEK293t cells with the expression vectors, the vectors were required to be 
packaged into lentiviral particles. Briefly, E.coli was transformed with several lentiviral 
packaging vectors: psMD2G, pmbl or pRSV by heat shock and selection on LB plates containing 
ampicillin. Colonies that were grew on the ampicillin plates were then used to seed 250mL 
cultures of TB media. The cultures were grown overnight at 37˚C with 225rpm shaking. The 
next day the bacteria were harvested, and the plasmid purified by maxiprep. The plasmid 
concentration was measured on a nanodrop and frozen at -80C until transfection. On a 6-well 
plate 750,000 cells were seeded and 3mL media was added to the cells. The next day the 
HEK293t cells were washed with Opti-MEM to remove the media and serum before being co-
transfected with the packaging vectors using Lipofectamine 2000. The amounts of each 
component are listed below (Table 14).  
The two solutions were made, mixed together and allowed to rest at room temperature for 
5 minutes before being added to the cells. The cells produced the packaged lentivirus for 2 days 
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before the media was collected, centrifuged at 1200rpm for 5 minutes to remove cell debris, 
filtered through a syringe filter (pore size 0.45um) and the supernatant stored at 4˚C. 
Table 14: Transfection of HEK293t components 
Tube A  Tube B 
Amount Component  Amount Component 
0.5mL OptiMEM  0.5mL OptiMEM 
2.5ug 
Expression vector 
(either eGFP or SGLT2) 
 10uL 
Lipofectamine 
2000 
   
1.25ug pMDL    
0.5ug pRSV    
0.5ug pMD2G    
 
To produce stably expressing human SGLT2 cell line, HEK293t were transduced with 
SGLT2 expression vector packaged into lentiviral particles (Figure 40). HEK293t cell were 
seeded at a density of 200,000 cells per well on a 6-well plate. The next day, the stored lentiviral 
particles (0.5mL virus) were diluted with 1.5mL media, and polybrene (stock was 10mg/mL; 
final concentration was 8ug/mL) and 2mL of this mixture was added per well. Enhanced green 
fluorescent protein was also transduced into cells as a positive control. The following day the 
virus was removed by aspirating the media and replacing with fresh media. Two days post 
transduction, puromycin (final concentration of 2ug/mL) was added to the cells to select for 
successfully transduced cells. Puromycin selection continued for two weeks. 
Expression of the proteins of interest were verified by qPCR and Western blot using the 
procedures previously described using the same Western blot antibodies and qPCR 
primers/probe sets. The antibody used to detect human SGLT2 was listed previously. To detect 
eGFP (Roche 11630500) was used at a dilution of 1:1000. 
93 
 
 
Figure 39: Lenti virus transduction procedure overview. The lentivirus containing the gene of interest is co-
transfected into a packaging cell line. The packaging cell line will produce pseudovirus particles containing the lenti 
virus which can be used to transducer a target cell line to stably produce the gene of interest after cell selection. 
Image from https://www.genecopoeia.com 
  
Lysis of the transduced HEK293t cells to release SGLT2 were attempted in several 
different conditions. Initially the cells were lysed by Radio Immuno Precipitation Assay (RIPA) 
buffer by itself, with sonication or with homogenization with a tissue homogenizer. Several 
different lysis buffers were used to solubilize the hydrophobic SLGT2 protein (Table 15). 
Laemmli buffer that was heated at 95C for 5 minutes and then added directly onto the cells was 
also used, however that created a viscous lysate that did not breakup after sonication and could 
not enter the gel during loading. 
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Table 15: Lysis buffers used to solubilize SGLT2 in transduced HEK293t cells overexpressing SGLT2 
RIPA buffer RIPA #2 CHAPs buffer Glycerol buffer 
150mM NaCl 150mM NaCl 30mM Tris-HCl pH 7.5 60mM Tris-HCl pH6.5 
1% NP-40 1% NP-40 150mM NaCl 25% glycerol 
0.5% Sodium 
deoxycholate 
2% Sodium deoxycholate 1% CHAPs 2% SDS 
0.1% SDS 2% SDS  
14mM B-
Mercaptoethanol 
50mM Tris pH8 50mM Tris pH8   
 
A FLAG tagged version of the SGLT2 expression vector was produced to provide an 
epitope for antibody binding. The sequence for the FLAG tag (amino acid sequence: 
DYKDDDDK) was inserted upstream of the SGLT2 ORF so that it would be expressed on the 
N-termini of the protein. A second vector containing the FLAG tag was also attempted. This 
vector would have the 4xGly-FLAG at its C-termini. To introduce the DNA sequence encoding 
FLAG tag Q5 Site-Directed Mutagenesis kit (New England Biolabs E0554) was used and the 
primers used are below (Table 16). 
Table 16: PCR settings for site directed mutagenesis and primers. The FLAG sequence is capitalized. 
Step Temperature Time Cycles 
Initial denaturation 98˚C 30 seconds 1 cycle 
Denaturation 98˚C 10 seconds 
25 cycles Annealing with temperature gradient 65˚C to 55˚C 15 seconds 
Amplification 72˚C 5 minutes 
Final extension 72˚C 2 minutes 1 cycle 
Hold 4˚C Forever 1 cycle 
 
N-terminal FLAG tag primers 
Forward primer 5'-gatgatgataaaGAGGAGCACACAGAGGCA-3' 
Reverse primer 5'-atctttataatcCATTCTCCCCAGGATCTGC-3' 
  
C-terminal FLAG tag primers 
Forward primer 5'-aaagatgatgatgataaaTAAGACCAACTGCGTTGG-3' 
Reverse primer 5'-ataatcccccccccccccGGCATAGAAGCCCCAGAG-3' 
 
95 
 
The FLAG tags were inserted into the SGLT2 expression vector using Q5 Site-Directed 
Mutagenesis kit. The SGLT2 expression vector was placed into two PCR tubes with one set of 
the primers. In the PCR reaction 12.5uL Q5 Mastermix was added to 10um forward and reverse 
primers, 25ng parental plasmid and 9uL water for a final volume of 25uL.  
After the PCR reaction the parental plasmid was digested with a supplied KLD mix and 
the PCR product was transformed into E.coli Stable bacteria (New England Biolabs C3040). The 
bacteria were spread onto LB agar plates containing ampicillin and grown in an incubator set at 
37°C. The next day the plates were removed and colonies that formed were grown in Terrific 
Broth (TB) media for plasmid DNA extraction. The TB media was cultured at 37°C with shaking 
at 250rpm overnight. The next day the cultures were centrifuged, bacteria collected and 
minipreps were conducted. The purified plasmids were sequenced in-house at Memorial Sloan 
Kettering Cancer Center using the following primers are in the Appendix. The insertion of the 
FLAG tag in either the N or C termini was confirmed using sequence alignment software 
BioEdit. Transient transfection with the N-terminal FLAG tag SGLT2 vector was made in 
HEK293t cells as previously described using Lipofectamine 2000. Expression of successful 
transduction was assayed by Western blot and qPCR. 
 
In vitro Uptake of Glucose Analogue 2-NBDG 
To assay the glucose transport function of SGLT2 expressed in the transduced HEK293t 
cells an in vitro uptake assay with the fluorescent glucose analogue 2-(N-(7-Nitrobenz-2-oxa-
1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG). The protocol was based on published 
procedure from other groups (235-237). HEK293t and transduced HEK293t cells overexpressing 
SGLT2 were plated onto 6-well plates. Two days later the cells were washed 3 times with Krebs 
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Ringer Hepes buffer with sodium choline (KRH choline buffer) and 1% bovine serum albumin. 
The cells were either untreated, received only vehicle (DMSO) or 2-NBDG. To each well 3mL 
KRH choline buffer containing 200um 2-NBDG was added (the final DMSO concentration was 
1.3%). The plates were incubated at for 1hour before being washed with KRH choline buffer. 
The cells were scraped off the plate, spun down at 300rcf and suspended in 200uL KRH choline 
buffer. The cells were sonicated and then diluted 1:1 with 50uL KRH choline buffer. The 
fluorescence of the 2-NBDG taken up by the cells was measured fluorescence excitation at 
485nm and emission at 550nm. 
 
In vitro Knockdown of eGFP with fCNT+sieGFP 
Expression of eGFP in HEK293t cells was knockdown by siRNA delivered by single-
walled CoMoCat fCNT. HEK293t cells had been transduced to overexpress eGFP. Cells were 
treated with either fCNT only, Lipofectamine with sieGFP, fCNT with sieGFP or no treatment. 
The HEK293t cells were transduced with an expression vector that would constitutively express 
eGFP. The expression of the gene was driven by the cytomegalovirus (CMV) promoter giving 
rise to robust expression. The commercially available Lipofectamine was used as a positive 
control in reducing the level of eGFP mRNA. 
 
 
Expression of Sglt2 in Mouse Tissues 
Expression of Sglt2 in mouse tissues were assayed for the by qPCR and Western blot. 
Five 7-month old female BALB/cAnN mice were euthanized and their heart, lung, liver, kidney, 
spleen, stomach, intestines and muscle were collected and frozen at -80°C. The tissues cut into 
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30mg fragments, lysis buffer was added (RIPA buffer for protein lysates or RNeasy buffer 
containing β-mercaptoethanol for RNA samples) and the tissues were homogenized at 25 
frequency for 3 minutes.  For qPCR  total RNA was used to synthesize cDNA (Quanta 
Biosciences, qScript cDNA Synthesis kit, cat no. 101414-106) using the following table for 
thermocycler settings (Table 17). After cDNA synthesis, (vol)ul of the cDNA was used for 
qPCR reaction. Primers and probes for mouse Sglt2 and Eukaryotic 18S ribosomal RNA were 
added to the reaction. 
Table 17: cDNA synthesis and qPCR settings for detecting SGLT2 in transduced HEK293t cells 
cDNA synthesis  qPCR cycling 
Time Temperature  Time Temperature Cycles 
5 minutes 25°C  30 seconds 95°C Once 
30 minutes 42°C  10 seconds 95°C 
Repeat 30 cycles 
5 minutes 85°C  30 seconds 68°C 
Infinite 4°C     
 
Immunohistochemistry (IHC) was completed on an array of mouse (brain, spleen, kidney, 
liver, lung) and human (testis) tissue samples and a polyclonal antibody towards Sglt2. The 
tissues were paraffin fixed and stained with anti-Sglt2 (Abcam ab85626) at a concentration of 
0.9ug/mL or 4.5ug/mL and with or without casein blocking (+D or –D, respectively). The 
secondary antibody was conjugated with HRP. 
 
In vivo Sglt2 RNAi in Mice with fCNT+siSGLT2 
To show that expression of Sglt2 could be knockdown with siRNA delivered by fCNT 
mice were treated with fCNT and siRNA specific for mouse Sglt2. Three control mice were 
injected with PBS while nine C57Bl/6J (3 months old female) mice were injected with fCNT+ 
siRNA specific for mouse Sglt2 (siSglt2). For three consecutive days mice were given a single 
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100uL injection of their respective treatment. The fCNT+siSglt2 group received injections with a 
1 siRNA:1 fCNT molar ratio so that the final concentration in the mouse’s blood would be 
0.1um fCNT. Three mice of the same litter were injected with 100uL PBS as controls. The mice 
were given one 100uL injection each day for 3 days and then on days 3, 5 and 7 three mice from 
the experimental group were sacrificed and their kidneys collected. The control mice were 
sacrificed on day 3. 
The kidneys were cut for qPCR and Western blot analysis. For qPCR, RNA was 
extracted as previously mentioned and 500ng total RNA was used for cDNA synthesis and 6uL 
of the cDNA product was used for the qPCR reaction. Each kidney was analyzed separately for 
qPCR while on Western blot protein lysate from only one kidney of each mouse was used. 
The procedures for Western blot are the same as in previous sections. After transfer onto a 
nitrocellulose membrane the blot was blocked with 5% milk for 1 hour before addition of the 
primary antibody (Abcam ab58298 1:1000) and the blot was incubated overnight with shaking at 
4°C. The primary antibody was washed away three times with TBST and then the anti-mouse-
HRP secondary antibody (BioRad 170-6516) was added and incubated for 1hr at room 
temperature. After incubation with the secondary antibody the blot was washed 3x with TBST 
and then imaged. 
To show that knockdown of Sglt2 in mice induced glucosuria the urine of mice treated 
with fCNT+siSglt2 was analyzed for glucose and sodium content. Ten mice were divided into 
two groups of five mice: one group received injections of PBS while the other group received 
fCNT+siSglt2. Mice were injected once a day for three consecutive days with either 100uL PBS 
or fCNT+siSglt2 in a 1 fCNT: 4 siRNA molar ratio in a volume of 100uL (final concentration 
0.2um in the mouse blood). On the fourth day the mice injected subcutaneously with 1mL PBS, 
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placed in isolation chambers. The isolation chambers were composed of a 1L glass beaker with a 
plastic funnel inside covered by plastic sheet to collect the urine and metal grids for the mice to 
walk on and prevent feces falling into the urine. The urine was collected 2 hours after the PBS 
injection and then the mice were sacrificed, blood and kidneys collected. The kidneys were cut 
into pieces for WB, qPCR and IHC using the procedures previously stated. 
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Results 
 
Chemical Functionalization and Physical Characterization of CoMoCat Single-walled 
Carbon Nanotubes 
Ammonium functionalized single-walled carbon nanotubes were produced as previously 
described in Chapter 1 and in published papers (91, 96, 97). After the functionalization reaction 
and purification to remove reactants, unreacted carbonaceous species and other impurities the 
fCNT were assayed for their chemical quality. Initial Kaiser assays showed that there was a high 
amount of ammonium groups present in the product, however after extensive dialysis against 
water Kaiser results yielded 0.5mmol amine/gram fCNT. This value was comparable to the 
previously published values of 0.3-0.5mmol amine/gram fCNT (91, 96). Likewise, reverse phase 
and size exclusion HPLC analysis showed that the CoMoCat fCNT behaved akin to previous 
batches of ammonium functionalized carbon nanotubes. 
To show that the ammonium functionalized CoMoCat fCNT could deliver RNAi to the 
kidneys in vivo the fCNT were first analyzed for binding ability with siRNA and second 
radiotracer labeled to determine tissue uptake. The fCNT were titrated with siRNA conjugated 
with the fluorophore Cy3 at either pH 5.5 or 7.4. At pH 5.5 titration data showed a binding 
affinity of 6.5nM and approximately 3 copies of siRNA per fCNT. At pH 7.4, physiological pH, 
the binding affinity was 10nM and each nanotube had roughly 2-3 siRNAs bound (Figure 40). 
This suggests that binding would bind relatively tightly while not being greatly affected by 
changes in pH from being transported from the mildly basic extracellular milieu to the acidified 
late endosome. 
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Figure 40: Binding of CoMoCat fCNT with siRNA-Cy3. Fluorophore labeled siRNA was titrated with fCNT at 
pH 5.5 (black) and pH 7.4 (red). siRNA bind fCNT with nanomolar affinity (left) at a ratio of about 2 siRNA:1 
fCNT (right). Both titrations showed binding ~10nM affinity with siRNA and ~2:1 ratio siRNA: fCNT. Two 
different fluorophore labeled siRNA were used human SGLT2 (hSGLT2-Cy3) and mouse Sglt2 (mSGLT2-Cy3). 
 
To determine tissue-specific uptake radiolabeled CoMoCat fCNT was biodistribution was 
done with male and female mice. The fCNT were conjugated with [
111
In]DOTA-Bz-NCS in a 
similar manner as in Chapter 1 to label the fVACNT. Radio HPLC showed that the radio 
conjugate greater than 95% radio purity with ~3% other species that was also labeled, possibly 
amorphous carbon that was carried over from the ammonium functionalization reaction (Figure 
41 top left and top right).  
Mice were injected with a single dose of the radiolabeled nanoparticle and after 1-hour 
they were sacrificed, and their tissues collected and counted for gamma particle decay. The male 
mice showed that a significant amount of radioactivity was excreted with the urine. It was not 
possible to collect the urine from the female mice due to technical reasons. The radio-conjugate 
was primarily taken up in the kidneys (nearly 40% in both male and females) and liver (~5%), 
the dorsal prostate (~5%) and the rest of the tissues assayed had negligible uptake (Figure 41 
bottom). The kidney uptake was significantly greater with this batch of CoMoCat fCNT than in 
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published data (91, 96). The increased renal uptake could provide more siRNA molecules 
delivered to the kidneys for more potent RNAi but why these nanotubes showed greater renal 
uptake was not a subject that was pursued. This was also the first time were looked at uptake of 
fCNT in the sex tissues (ovaries, three lobes of the prostate and testes) which showed negligible 
uptake except the dorsal prostate. This indicates that they would not be viable RNAi targets with 
fCNT. 
 
Figure 41: Radiolabeling of CoMoCat fCNT and biodistribution. CoMoCat fCNT were radiolabeled with 
DOTA-Bzn and Indium-111. HPLC analysis of the radiolabeled construct showed similar elution profile to fCNT 
(top left panel) and ~97% radio purity while there was ~3% other species present (top right panel). Male (black) and 
female (red) mice injected with indium labeled fCNT and showed similar uptake profiles (bottom). Uptake was 
primarily in the kidneys (~40%ID/g tissue) and much less in the liver (~3%ID/g). The majority of the radioactivity 
had been excreted out as urine. 
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Human SGLT2 Expression in in vitro Models 
Expression of SGLT2 protein and mRNA were examined in three primary kidney cells 
and various cancer cell lines. The primary kidney cells were derived from healthy human 
cadavers and the three samples were isolated from either cortical epithelial, medulla cells or 
proximal tubule cells by Lifeline Cell Technology. Of the cancer cell lines two, HEK293t and 
HK-2, are derived from kidney origins while two colorectal cell lines, SW480, Caco-2 Meso37, 
Jurkat. This potentially provided a wide spectrum of possible in vitro models to study.  
Literature has pointed to high expression of SGLT2 (gene symbol SLC5A2) in the human 
kidney cortex, kidney proximal tubule cells and in primary lesions of lung cancers and 
adenocarcinomas (238-240). The colorectal cell lines SW480 and Caco-2 were expected to 
express SLC5A1 but not SLC5A2 (241), providing validation for the specificity of antibodies and 
qPCR primers/probes that would be used in the future. Finally, Jurkat and Meso37 cells are 
derived from human T lymphocytes and not expected to have expression of SLC5A2 or SLC5A1 
and could be used as negative controls. However, initial examination of these models showed no 
SGLT2 mRNA transcripts and questionable Western blot results were inconclusive (Data not 
shown). 
Amplification by qPCR showed no SLC5A2 mRNA present in the in vitro models. While 
the reference gene, TBP in the qPCR reactions all showed consistent amplification with Cq = 
~26, SLC5A2 did not show amplification (Data not shown). One potential reason for this would 
be the relatively low number of mRNA transcripts present in the cells. To further probe this 
hypothesis, the number of amplification cycles during qPCR was extended from 35 cycles to 45 
and the amount of cDNA added to each reaction from 2uL to 5uL. Again, the reference gene 
amplified consistently with Cq = ~26 while SLC5A2 had Cq values = ~40. The relatively high 
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and inconsistent Cq values suggested random annealing and amplification by the primers/probe 
rather than specific amplification of the target gene. 
In addition to examining expression of SGLT2 mRNA by qPCR, Western blot analysis 
was done to scrutinize protein translation. Western blots of the three primary kidney cells and 
cancer cell lines used in the qPCR showed inconclusive results. SGLT2 has a calculated 
molecular weight of 75kDa based on its amino acid sequence. The value has been used in many 
references but puzzlingly SGLT2’s sequence contains several potential N-linked glycosylation 
sites which would add to the molecular weight of the protein. This peculiarity has not been 
addressed in the literature. 
Western blots were stained with various commercially bought antibodies towards human 
SGLT2 and SGLT1. Several of these showed a faint band at 75kDa in the primary renal cortical 
cells was well as in other in vitro models when stained with several of the SGLT2 specific 
antibodies. SGLT2 was expected to be highly expressed in primary kidney cortical epithelial 
cells but the Western blots showed only faint staining. 
Intriguingly, Meso37 cells showed greater staining of SGLT2 and SGLT1 than the 
primary kidney cells under reducing and nonreducing conditions. This is contradictory to 
previous data as Meso37 is a mesothelioma cell line. Furthermore, SGLT2 staining was visible in 
SW480 cells when the protein lysate was reduced but much less so when protein lysates was not 
reduced. These results could point at the nonspecific binding of the antibody as the cell line 
SW480 was derived from colorectal adenocarcinoma. Being from the colon it would be expected 
to express SGLT1 but not SGLT2. The antibody used may have inadvertently bound to SGLT1 
or another protein similar a similar epitope. Also, the lower intensity band when the SW480 
protein lysate was not reduced poses the possibility that SGLT2 was insoluble during preparation 
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of the samples. SGLT2 is a 14-transmembrane integral protein suggesting that much of its 
sequence contains hydrophobic regions. This could have caused the protein to precipitate or 
aggregate while the protein lysate was being prepared in non-reducing conditions. 
It was concluded that the in vitro models examined were poor candidates for SGLT2 
expression. The qPCR data suggested that there was either no or extremely low abundance of the 
mRNA transcripts while the Western blots did not show convincing evidence that SGLT2 was 
expressed. To overcome this issue an overexpression model for SGLT2 was generated in 
HEK293t cells. 
Overexpression vectors for SGLT2 and eGFP were obtained from GeneCopoeia, the open 
reading frames for these genes were inserted into the vector pEZ-Lv105 and confirmed by 
sequencing the insert. Lentiviral particles of the two expression vectors were produced separately 
by co-transfecting HEK293t cells with the expression vectors packaging vectors psMD2G, pmbl 
and pRSV. The viral particles were harvested and then used to produce stably expressing cell 
lines by transducing HEK293t cells with the packaged virus. After selection with puromycin, a 
premature protein translation termination drug, the cell lines were tested for expression of 
SGLT2 and eGFP. 
SGLT2 and eGFP mRNA and protein expression in transduced cells were inspected by 
Western blot and qPCR using the same probes that were used for interrogating cancer cellines 
and primary kidney cells. The eGFP control transduction showed immediate expression of the 
fluorescent protein under fluorescence microscopy (Data not shown). Western blot and qPCR 
results further confirmed the successful transduction with the eGFP vector (Figure 42). 
Transduction with the SGLT2 lentivirus was successful however SGLT2 protein 
expression did not increase in the transduced cell line. The results from qPCR showed a 
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substantial increase in SGLT2 mRNA transcripts compared to untransduced HEK293t cells and 
HEK293t cells transduced with eGFP virus. SGLT2 protein however did not increase compared 
to controls. This discrepancy was confounding and based on previous results from examination 
of other possible in vitro models; it was hypothesized that the SGLT2 protein could be 
aggregating or not fully solubilized in lysis buffer. 
 
Figure 42: Overexpression of human SGLT2 and eGFP in HEK293t cells. HEK293t cells were transduced with 
either vector for expressing human SGLT2 or eGFP. SGLT2 mRNA quantification by qPCR (top left panel) and 
eGFP (bottom left) mRNA expression quantified by qPCR results comparing untransduced, transduced with eGFP 
and mouse kidneys. Western blot showing expression of SGLT2 and eGFP in transduced HEK293t cells (top right). 
Untransduced and cells transduced with only the eGFP expression vector show SGLT2 protein possibly basal level 
expression in the cells. Western blot of transduced SGLT2 or eGFP cells lysed by sonication or homogenization to 
release SGLT2 from the cell membrane.  
 
A series of different cell lysis methods and buffers were tested to optimize extraction of 
the transmembrane protein (Figure 43). Cells were subjected to lysis by homogenization and 
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sonication as well as lysis in buffer alone to expel the hydrophobic transporter from the insoluble 
cell membrane fraction. Several cell lysis buffers were also tested in hope of solubilizing the 
protein. However, none of the trials appeared to show improved SGLT2 separation. This 
suggested that although SGLT2 mRNA was transcribed at a significant volume, the protein was 
not being translated within the cells accordingly. 
 
Figure 43: Western blot of SGLT2 transduced HEK293t lysed by different lysis buffers. Several different lysis 
buffers were used to improve yield from cell lysis of HEK293t cells overexpressing SGLT2. Each buffer was used 
to solubilize transduced and untransduced cells as a control. There was no difference in protein extraction between 
the five buffers tested. 
 
 To further investigate whether the transduced HEK293t cells were expressing SGLT2 a 
fluorescent glucose uptake assay with 2-NBDG was used. This assay would allow determination 
if there was an increase in the protein, but direct detection of the amplified levels with an 
immunoassay was ineffectual. The fluorescent glucose analogue 2-NBDG (fluorescent excitation 
at 465nm and emission at 540nm) was introduced to the cells and if imported into the cell it will 
not be able to proceed through glycolysis nor escape from the cell. Additionally, SGLT2 is a 
symporter requiring the import of sodium to transport glucose into the cell. By replacing sodium 
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from the media with choline chloride uptake of 2-NBDG is mediated by SGLT2 would be halted. 
In samples that were untreated or treated with only the vehicle (DMSO) there was little to no 
fluorescence detected (Figure 44 left panel). When sodium chloride was replaced with choline 
chloride in the KRH buffer the fluorescence detected within the transduced cells is like that of 
the cells with sodium present in the buffer (Figure 44 right panel). This confirms that there is 
no increase in SGLT2 protein present on the surface of the transduced cells as the transport of 2-
NBDG is not sodium dependent but by another glucose transporter. 
 
Figure 44: SGLT2 transduced cells do not show increased uptake of fluorescent glucose analogue 2-NBDG. 
Uptake of the of the fluorescent glucose analogue 2-NBDG was tested in HEK293t transduced to overexpress 
SLGT2 cells (left). SGLT2 requires sodium cotransport to import glucose into the cell. There was no difference in 
uptake of 2-NBDG when cells when sodium in the buffer was replaced with choline. When compared to 
untransduced HEK293t the transduced cells showed no difference in 2-NBDG uptake (right). 
 
 As an attempt at improving detection of SGLT2 in transduced cells overexpressing 
SGTL2, FLAG epitope tagged expression vectors were produced. The FLAG epitope tag 
consists of the amino acid sequence: DYKDDDDK. An N-terminal and a C-terminal FLAG 
tagged expression vectors were produced by site-directed mutagenesis to introduce EcoRI 
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restriction sites downstream of the ATG start codon for the N-terminal construct or just prior to 
the stop codon for the C-terminal vector. The C-terminal construct also contained four glycine 
residues upstream of the FLAG tag to ensure that the tag would protrude from the plasma 
membrane. The constructs were produced by cloning the FLAG inserts flanked by EcoRI sites 
into the mutated vectors.  
 The N-terminal FLAG construct was produced, and sequencing of the insert showed the 
FLAG sequence was properly inserted in the desired location. The N-terminal FLAG SGLT2 
expression vector was transiently transfected into HEK293t cells. Analysis by qPCR showed an 
increase in SGLT2 mRNA however Western blot analysis did not show a change in the protein’s 
expression level (Data not shown). The C-terminal vector was not produced due to issues with 
cloning the 4xGly-FLAG sequence into the expression vector. Several attempts were made to 
ligate the sequence into the vector but sequencing of the insert showed none of the clones 
contained the correct insertion (Data not shown). 
 
In vitro Knockdown of eGFP with fCNT+sieGFP 
Expression of eGFP in HEK293t cells was silenced by single-walled CNT carrying 
siRNA. HEK293t cells had been transduced to overexpress eGFP as previously mentioned. Cells 
were treated with either fCNT only, Lipofectamine with sieGFP, fCNT with sieGFP or no 
treatment. The results from qPCR show that fCNT alone had a negligible effect on the 
expression of eGFP mRNA while Lipofectamine with specific siRNA decreased eGFP mRNA 
levels by nearly 25%. Functionalized nanotubes with sieGFP were also able to decrease the 
mRNA levels by about 15% (Figure 45). 
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The HEK293t cells were transduced with an expression vector that would constitutively 
express eGFP. The expression of the gene was driven by the cytomegalovirus (CMV) promoter 
giving rise to robust expression. The commercially available Lipofectamine was used as a 
positive control in reducing the level of eGFP mRNA. Based on the qPCR results it appears that 
these transduced cells eGFP expression was highly robust. With the commercially available 
transfection reagent there was only a 25% decrease in mRNA. 
 
Figure 45: In vitro knockdown of eGFP in HEK293t cells. Cells over expressing eGFP were treated with either 
PBS (labeled Untreated on the plot), fCNT only, Lipofectamine with specific to eGFP (Lipo+sieGFP) or fCNT with 
sieGFP (fCNT+sieGFP). The lipofectamine group showed ~25% decrease in eGFP mRNA while fCNT with 
specific siRNA showed ~15% decrease. 
 
Expression of Sglt2 in Mouse Tissues 
Examination of Sglt2 expression in vivo was then analyzed when a suitable in vitro model 
was not found. Expression of Sglt2 in mice was probed by Western blot and qPCR. Normal 
healthy mice were euthanized and their hearts, lung, liver, kidney, spleen, stomach intestines and 
muscles were collected. The gene coding for Sglt2 in mice is Slc5a2. The mRNA transcript for 
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murine Sglt2 was detected exclusively in the kidneys of the tissues examined (Figure 46). The 
protein however was found to be present in the liver, kidney, stomach, spleen and intestine by 
Western blot analysis; suggesting that the antibody was not stringently specific as desired. 
 
Figure 46: Expression of SGLT2 in mouse tissues. qPCR results showing SGLT2 mRNA (SLC5A2) is only 
expressed in the kidneys of mice (left). Western blot showing SGLT2 protein (75kDa) expression in several mouse 
tissues, most notably in the kidneys and liver. There may have been cross reactivity of the primary antibody used in 
the Western blot with proteins with similar epitopes such as Sglt1. 
 
IHC staining of mouse and human tissues showed that there was specific staining of 
murine Sglt2 in the kidneys but there was also nonspecific staining in the brain, liver and human 
testis (Figure 47). Staining with a negative control antibody showed diffuse and homogeneous 
staining throughout the brain, liver and human testis indicating the nonspecific staining in those 
tissues (see Figure 57 in the Appendix). Conversely, the kidney showed punctuated staining in 
the lumen of Proximal Tubules (indicated by black arrows in the Figure 48) in the kidney cortex. 
The kidney cortex can be identified by the presence of glomeruli (pointed by white arrows in 
Figure 48), which appears as a globe containing dozens of blue nuclei. The kidney medulla 
however, lacks the presence of glomeruli and Sglt2 expression. The IHC staining coincides with 
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other groups who have found it predominately in the kidney cortex (201-203, 206, 207, 209). 
There may be additional tissues, such as the pancreas that express Sglt2 but the panel of mouse 
tissues that was provided did not include those tissues (142, 242). 
 
Figure 47: Sglt2 protein expression in mouse tissues. Mouse tissues were stained with anti-Sglt2 and then a 
secondary antibody conjugated with Horse Radish Peroxidase was used to target the primary antibody. The spleen, 
lung and intestines show no staining for Sglt2 while the brain, liver and human testis show staining however it 
appears to be background staining or nonspecific staining. The kidneys showed specific staining in the cortex 
surrounding the lumen of Proximal Tubules. All images are at 5x magnification and the black scale bars represent 
200um. Cell nuclei are stained blue with DAPI and Sglt2 is brown. 
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Figure 48: Sglt2 protein expression in mouse kidneys. Mouse Sglt2 is expressed exclusively in the cortex of the 
kidney. The black arrows indicate Sglt2 expressed within the lumen of the Proximal Tubules. White arrows point at 
the polynucleated glomeruli, which are only present in the kidney cortex. Mouse cortex and medulla regions are 
shown in red text. Cell nuclei are stained blue with DAPI and Sglt2 is brown and the scalebar (lower left) represents 
100um. 
 
In vivo Sglt2 RNAi in Mice with fCNT+siSGLT2 
The expression of Sglt2 in mice has been knockdown with CoMoCat fCNT carrying 
specific siRNA. In the first experiment mice were treated for three consecutive days with a single 
injection of PBS or fCNT+siSglt2. On the fourth day the mice were sacrificed, and their kidneys 
collected for Western blot and qPCR analysis of Sglt2. In the first RNAi experiment nine mice 
were injected with fCNT+siSglt2 while 3 were injected with PBS on day three the control mice 
and three mice from the experimental group were sacrificed and then on day 5 and 7 an 
additional three mice were sacrificed. 
Based on qPCR results there was a 40% decrease in mRNA of Sglt2 compared to the 
PBS group on days 3 then on day 5 and 7, after the administration of the fCNT+siSGLT2 drug 
was discontinued, SLC5A2 mRNA levels appear begin to rebound back to the level of the control 
group (Figure 49). Although the GAPDH loading control bands were not equal in all lanes on 
the blot which may cause misleading conclusions, the expected trend is apparent. On days 3 and 
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5 there is less Sglt2 protein than compared to the control mice. Curiously, on day 5 there is even 
less Sglt2 than on day 3 suggesting that there may be a delay from when the mRNA levels 
decrease to when the protein levels respond. There may have been a few days wait for the 
SGLT2 present on the surface of the cells to turn over and become recycled within the cytosol. 
 
Figure 49: Silencing of Sglt2 in vivo mediated by fCNT+siSglt2. Mice were treated for three consecutive days 
with either PBS or fCNT+siSglt2. Three mice from the experimental group and control mice were sacrificed on days 
3, on days 5 and 7 the remaining animals were sacrificed. qPCR data showing decreased Sglt2 mRNA expression 
(bottom left) there was a significant decrease (p = 0.0361) on day 3 compared to the control mice and similar 
decrease on days 5 and 7 but it was not statistically different (p = 0.0861 and p = 0.1393, respectively). Kidneys 
from collected for Western blot analysis showed decreased protein expression in mice treated with fCNT+siSglt2 
(bottom right). One kidney from each mouse on days 3 and 5 were taken and run on Western blot.  
 
In the second RNAi experiment mice were again treated with either PBS or 
fCNT+siSGLT2 for three consecutive days but on the fourth day the mice were fasted overnight 
and then on the fifth day mouse urine was collected for analysis. The previous RNAi experiment 
showed that fCNT+siSglt2 caused Sglt2 mRNA levels to decrease and then protein levels would 
follow. For this experiment the question was if the decreased protein levels would lead to 
increased excretion of glucose and sodium.  
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Urinalysis showed an increased amount of glucose in the mice treated with fCNT+siSglt2 
compared to PBS or fCNT only treated mice (Figure 50). However, high variation was observed 
even between mice of the same treatment group. This result is possibly akin to FRG patients who 
lack functioning SGLT2. An FRG patient excretes variable amounts of glucose in their urine and 
in some cases none at all (243-248). The small decrease in blood glucose may also be used as an 
indicator of increased urine excretion. 
 
Figure 50: Silencing of Sglt2 induces glucosuria in mice. Mice were treated with PBS, fCNT only or 
fCNT+siSglt2 for three consecutive days, fasted overnight before urine collection and then euthanized on day 5. 
Control mice treated with PBS or fCNT only show relatively the same amount of glucose excretion (bottom left). 
Mice treated with fCNT+siSglt2 caused an increase in glucosuria however the results varied greatly from animal to 
animal in the experimental group. There was also a small decrease in the blood sugar levels of the mice treated with 
fCNT+siSglt2 compared to controls (bottom right). 
 
In a follow up experiment, mice were treated in a similar dosing regimen to see if the 
results of the previous experiments were reproducible. Mice were treated for three days with 
either PBS or fCNT+siSglt2 and on the fourth day urine, blood and the kidneys were collected. 
Urinalysis showed that mice treated with fCNT+siSglt2 showed increased glucose and sodium 
excretion confirming the previous experiment’s results, again high variation from animals in the 
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same group was detected (Figure 51 top row). Blood glucose levels again showed a small 
decrease compared to controls (Figure 51 bottom left). Furthermore, qPCR results showed 35% 
decrease in mRNA levels compared to PBS treated controls, similar to the first knockdown 
experiment (Figure 51 bottom right). 
 
Figure 51: Knockdown of Sglt2 in mice causes glucose and sodium excretion. Mice were injected for three 
consecutive days with either PBS or fCNT+siSglt2 and then on day 3 urine, blood and kidneys were collected. The 
mice in the experimental group showed increased glucose excretion (top left panel; p = 0.0417) as well as sodium 
loss (top right panel; p = 0.1322) their blood glucose levels decreased slightly (lower left panel) and qPCR showed a 
decrease in Sglt2 mRNA as well (lower right).  
 
Immunohistochemistry (IHC) staining of the mouse kidneys from this experiment 
showed an increase in Sglt2 protein in the experimental group compared to the PBS treated 
group (Figure 52 and Figure 53). This may be an issue of mixing up samples as the urine and 
qPCR data show the opposite trend. 
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Figure 52: Silencing Sglt2 by RNAi delivered via fCNT decreases Sglt2 protein levels. IHC images of the 
kidneys from mice treated with PBS or fCNT+siSglt2 show decreased Sglt2 staining in the kidney cortex of mice 
treated with PBS (left). Quantification of IHC staining versus DAPI staining confirmed less Sglt2 staining in the 
PBS treated mice (p = <0.0001) (right). Brown staining is Sglt2 protein and the blue staining is cell nuclei with 
DAPI. Images are at 5x magnification. Note: At the time of kidney collection, the samples were placed into the 
wrong cassettes for tissue fixing and all subsequent images and data corresponded to that error. 
 
 
Figure 53: Enlarged images of mouse kidneys stained for Sglt2 after RNAi. Images are all 5x magnification. 
Note: At the time of kidney collection, the samples were placed into the wrong cassettes for tissue fixing and all 
subsequent images and data corresponded to that error (e.g. kidneys from mice in the treatment group were placed in 
cassettes labeled for the PBS). The scale bars (lower left) represent 50um. 
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Discussion 
 
Single-walled CoMoCat fCNT were chemically modified and characterized by HPLC, 
Sarin assay, siRNA binding and biodistribution. Data from these fCNT showed similar properties 
as previously published data of ammonium functionalized single-walled carbon nanotubes. After 
confirming this batch of functionalized CNT showed similar physical and pharmacokinetic 
properties as well as the ability to silence gene expression in vivo, identifying a model system for 
studying RNAi directed towards SGLT2 was the next step.  
SGLT2 is a complex multi-pass integral transmembrane protein. Expression of SGLT2 in 
humans has been disputed, but the consensus in the field is that it plays a vital role in renal 
glucose reabsorption. Several small molecule drugs of the gliflozin family have been approved 
by the FDA to inhibit the transporter to treat hyperglycemia in Type 2 Diabetes Mellitus. The 
effects of these drugs have shown promising results including decreasing blood glucose sugar, 
A1C levels and hypertension. In my work I show that murine Sglt2 expression can be silenced 
with siRNA delivered by functionalized single-walled carbon nanotubes. 
Expression of SGLT2 was assessed in several cancer cell lines but failed to show 
persuasive evidence that functioning SGLT2 protein was expressed in these models. Although 
Western blots showed that there was a possible protein band corresponding to the molecular 
weight of SGLT2 (75 kDa), qPCR data did not show convincing expression of the mRNA 
transcript in those cell lines. Rather, qPCR data showed that there was no SGLT2 mRNA present 
in the models examined. In vitro models expression of SGLT2 has been ambiguous as there is no 
consensus on both the mRNA and protein expression found. 
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Primary kidney cells did not display convincing expression of SGLT2. The primary cells 
were isolated from a human cadaver but did not show amplification of the gene under qPCR and 
only had a faint band at the expected molecular weight of SGLT2. It was surmised that the 
primary cells lost their expression of SGLT2 after they were extracted from the donor, cultured 
and passaged multiple times. This could have caused changes in gene expression allowing the 
cells to grow and thrive in a foreign environment. The cells transitioned from a hypoxic 
environment where they grew in a 3-dimensional tissue with signal factors from other cells and 
tissues to a plastic surface growing as a monolayer with relatively high oxygen concentration 
(95% O2 with 5% CO2). Contamination from other cell types from the donor’s kidney could also 
cause outgrowth of the competing cell type. Finally, lot-to-lot variability of the cells can greatly 
affect the quality and purity of the cells. 
An in vitro overexpression model of SGLT2 was then created in HEK293t cells to 
ameliorate the issue of identifying a cell that expresses SGLT2 robustly. Although mRNA levels 
in the transduced cells were significantly higher than both non-transduced cells, there was no 
difference in the protein expression between the control and SGLT2 transduced cells. To further 
assay if there was increased protein expression several monoclonal and polyclonal antibodies for 
SGLT2, lysis and buffer conditions were tested to determine an optimal lysis procedure for the 
extracting the elusive SGLT2. Uptake of the fluorescent glucose analogue 2-NBDG was tested in 
the transduced cells as a functional assay of determining SGLT2 protein expression in vitro. The 
results indicated that increased uptake of 2-NBDG was mediated by a sodium independent 
glucose transporters and not SGLT2. Finally, expression vectors containing the FLAG epitope 
tag was produced for the N-termini of SGLT2 but failed to be detected by Western blot analysis. 
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Unfortunately, all efforts pointed to the conclusion that although the mRNA was 
increased significantly compared to the controls there was no increased protein translation in the 
transduced cells. Perhaps the expression of SGLT2 in the transduced cells is like a printer 
receiving dozens of requests to print out a lengthy document that also needed to be double sided, 
collated and stapled. After it finishes several copies the paper becomes jammed in the system and 
cannot continue producing the finalized document leading to a backup in the print queue.  
The lack of protein translation may have been due to the complexity of the transporter. 
As mentioned previously SGLT2 contains 14 transmembrane domains and post translational 
modifications both of which need to be completed in the Endoplasmic Reticulum (ER). During 
the synthesis of transmembrane proteins ribosomes translocate to the rough ER with the nascent 
peptide. There the peptide is threaded back and forth through the membrane to properly insert the 
transmembrane regions into their appropriate orientation. This may be an arduous task for cells 
to SGLT2 overexpression in vitro is a difficult task and there is currently no crystal structure 
suggesting that either producing large quantities of the protein or removing it from its 
hydrophobic environment is quite a feat to accomplish. Private message with Dr. Ernest M. 
Wright (UCLA) confirmed the difficulty of producing in vitro SGLT2 overexpression models. 
Furthermore, co-factors (activators, chaperones or post translational modifications) may be 
required in proper folding of some proteins (221-224). It has been reported that MAP17 may be 
one such co-factor (221, 222). Co-expression of MAP17 with SGLT2 appears to activate and 
increase the rate of glucose transport SGLT2 without increasing protein expression, but it is not 
fully understood why. 
Forgoing an in vitro model to study, expression of the glucose transporter in mice 
(abbreviated Sglt2 to differentiate from the human of the protein) was interrogated. Expression 
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of the protein has been confirmed in the Proximal Convoluted Tubules of the kidneys; however, 
there is debate whether Sglt2 is expressed in other tissues. The heart, lungs, liver, kidneys, 
spleen, stomach, intestines, muscle were collected from healthy mice and Sglt2 expression was 
surveyed by Western blot and qPCR. Protein expression was seen in several tissues while the 
mRNA was detected solely in the kidneys. It is not clear why Western blot data showed a protein 
band of the molecular weight of 75 kDa in liver, spleen and intestines in similar intensity as the 
kidneys but there were no mRNA transcripts detected by qPCR. One possibility may be that the 
monoclonal antibody used was cross reactive with other members of the SGLT family such as 
SGLT1. Immunohistochemistry staining of mouse tissues with a polyclonal antibody showed 
specific staining of in the kidneys of mice while there was non-specific staining in the human 
testis and mouse liver and brain (Figure 56). 
Initial knockdown experiments showed that both protein and mRNA of Sglt2 decreased 
with treatment of fCNT+siSGLT2. When dosed for three consecutive days with PBS or 
fCNT+siSGLT2, mice treated with fCNT+siSGLT2 showed ~40% decrease in mRNA 
transcripts on the third day when the mRNA was at its lowest and then was slowly increasing 
back to the same levels as the control group. On the other hand, the Sglt2 protein showed its 
nadir on the fifth day, possibly due to slow protein turnover. The functioning Sglt2 protein on the 
surface of the PTC cells may require time to be brought back into the cytosol and degraded. 
Because of loss of Sglt2 function, glucose is excreted in mice treated with 
fCNT+siSGLT2. It was expected that glucose would be excreted when Sglt2 expression is 
knocked down the glucose that passes through the kidneys is not reabsorbed but continues 
through the nephron and collected in the urine. However, in the mice treated with 
fCNT+siSGLT2 there was a highly variable amount of glucose that was excreted with several 
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mice excreting the same amount as the control animals while two others were excreting 
exceptionally high amounts of glucose. One possible explanation is that the glucose excretion in 
the mice is akin to the large variability of glucose excretion in Familial Renal Glucosuria (FRG) 
patients (243-248). FRG patients have a loss of function mutation in the SLC5A2 gene encoding 
leading to loss of SGLT2 protein expression. Other side effects noticed when Sglt2 expression 
was knockdown was the increased excretion of sodium and a marginal decrease of blood glucose 
levels. These results coincide with the hypothesis that glucosuria can be induced by RNAi 
mediated by fCNT in vivo. 
Glucose present in the urine of mice treated with fCNT+siSglt2 was a convincing piece 
of evidence for successful silencing of Sglt2 in the kidney cortex. However, collection of mouse 
urine is a difficult feat as they only excrete 1mL urine/day making it a tedious chore to collect 
sufficient quantities (249-255). Ideally metabolic cages can be used to house and collect mouse 
urine, but they are costly and require a large footprint in the lab. Methods of urine collection 
have been published (249-254, 256-262) and several methods were tried but none were facile or 
reliably produced sufficient volumes for analysis. Additionally, several other problems propped 
up as urine collection methods were tested the most challenging was reproducibility of results. 
Ideally, a set of metabolic cages to house a mouse individually and provide food/water would be 
the best option. However, those cages are costly and require a large amount of space in a 
lab/vivarium (263).  
The procedure below was found to be most optimal for collecting the urine in the most 
humane method. For our studies we were focused in the concentration of glucose present in the 
urine. The total volume and total amount of glucose was irrelevant to us. By injecting saline 
buffer into the scruff of each mouse this increased the volume of liquid processed by the kidneys 
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(Figure 56). In the control mice treated with only PBS their kidneys would still be able to 
reabsorb the glucose that passed through the nephrons. On the other hand, mice that were treated 
with fCNT+siSglt2, their Sglt2 expression was lower and the glucose passing through the 
nephron would continue down the path until it was either reabsorbed by another glucose 
transporter or collected with the urine in the bladder, as per usual. The urinalysis data of samples 
collected with this method showed relatively low variation in the control group. Moreover, blood 
glucose levels in the treatment groups also showed trends that agreed with our hypothesis; 
increased glycosuria would lead to lower serum glucose levels. 
 Although there was substantial variability in the levels of glucose excreted the work 
presented here shows that silencing of Sglt2 in vivo did indeed lead to glycosuria. Silencing 
expression of Sglt2 in vivo shows a similar phenotype to patients who have a mutation in the 
gene encoding SGLT2 leading to a nonfunctioning protein product and generally benign 
condition of FRG (243, 244, 264-266). Like FRG patients the mice here showed variable glucose 
excretion form the samples collected (138, 265, 267-269). This may be due to redundant glucose 
reabsorption mechanisms in the nephron downstream of SGLT2; a consequence of the need to 
retain the precious glucose in the body. Others have shown that when SGLT2 expression is 
completely abolished in knockout mice, Sglt1 or another glucose transporter can reabsorb some 
of the glucose passing through the nephron as a compensatory measure.  
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Summary and Future Directions 
 
 Manipulation of an organism’s phenotype by RNAi can provide an indispensable tool in 
understanding gene function or as a therapeutic agent. Unfortunately, several major hurdles 
needed to be surmounted before the first siRNA-based therapy could be FDA approved in 2018. 
One of the most difficult hurdles has always been tissue-specific uptake which limited the 
number of diseases that could be treated in vivo to the kidneys or other accessible tissues. This 
leaves many other tissues and cells insusceptible.  Here we explored the feasibility of several 
fibrillar nanoparticles in expanding number of possible RNAi targets to the renal system. This 
work with fibrillar nanoparticles has increased the potential targets in vivo for gene silencing by 
taking advantage of the unique pharmacokinetic profile of the particles conferred by their rod-
like shape.  
Current RNAi therapies in development primarily target the liver or other easily 
accessible delivery site, limiting the number of potential disorders that RNAi can be applied to. 
Unlike large globular particles, such as antibodies (~150kDa) which can circulate in the plasma 
for long periods of time our fibrillar nanoparticles, weighing in excess of 200kDa, show fast 
renal clearance within hours post injection. Not only can these nanoparticles clear quickly in vivo 
but they are also internalized by cells in the kidneys. This broadens the avenue of gene targets to 
silence and possible disorders.  
Ammonium functionalized Vertically Aligned Carbon Nanotubes showed nanomolar 
binding affinity with fluorescently labeled siRNA. Whiles lacking critical information such as 
the number of walls within the VACNT several crude estimations of the VACNT’s molecular 
weight were made giving a broad range of weights. Using that approximation, it was determined 
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that delivery of a foreign gene to the kidneys or liver mediated by fVACNTs may be possible. 
Delivery of an exogenous gene can further expand the repertoire of tools that can be used for 
treating renal specific disorders. As a next step in work with the fVACNTs empirical 
determination of the molecular weight, possibly by Analytical Ultracentrifugation, and in turn 
the size of an expression vector that can be delivered should be made. 
The homogeneous nature of VACNT can be attributed to their production method where 
the VACNT are grown as a forest of nanotubes endowing highly uniform multi-walled 
nanotubes. Moreover, Hitachi’s production method to generate VACNT between 1-5um in 
length may allow us to either increase the number of siRNA molecules transported by the 
fVACNT or increase the size of a potential transgene. Of course, the increased length of a 5um 
long VACNT may not display Fibrillar Pharmacology nor uptake in the kidneys. 
 Work with cellulose nanocrystals demonstrated robust gene knockdown in vivo and in 
vitro. Cellulose nanocrystals ($1000/kilogram of an 8.0% w/w slurry) may be a more cost-
effective alternative to carbon nanotubes; costing ~$12/gram compared to CNTs which costs 
nearly 60 times more ($714/gram). Chemical modifications of the CNC surface to increase water 
solubility and append cationic ammonium groups. Physical characterization showed improved 
water solubility compared to the starting material. In vitro and in vivo silencing of eGFP 
illustrated viable gene knockdown via fCNC. The work here was the first time an in vivo gene 
silencing has been shown utilizing functionalized cellulose nanocrystals. 
 Proposal of treating Type 2 Diabetes with RNAi mediated by fCNT was made. The sugar 
transporter SGLT2 is the principle mechanism for reabsorption of glucose in the kidneys to 
prevent its loss through urine excretion. This work demonstrated silencing the expression of 
renal Sglt2 in mice decreased mRNA and protein levels the target. Additionally, blood sugar had 
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a minor decrease and while urine sodium and glucose excretion were increased indicating a 
decreased in sodium dependent glucose transport. This novel method of preventing renal glucose 
reabsorption Translation of this work into a diabetic/hyperglycemic mouse model should be 
tested.  
This work explored the early development of several fibrillar nanoparticles as potential 
RNAi delivery platforms. Carbon nanotubes and cellulose nanocrystals were chosen for study in 
this work due to their robust physical properties, ability to be readily chemically modified and of 
course their fibrillar nature. Ultimately, it would be of great elation if any of these three 
nanoparticles would be approved for use in therapeutic applications.  
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Appendix 
Table 18: Oligonucleotide sequences used 
Sequences 
sieGFP 
Antisense 5’-rGrCrArArGrCrUrGrArCrCrCrUrGrArArGrUrUrCrArUrUrU -3’ 
Sense 5’-rArUrGrArArCrUrUrCrArGrGrGrUrCrArGrCrUrUrGrCCG -3’ 
eGFP 
genotyping 
primers 
GFP173-F 5’-GAGCTGAAGGGCATCGACTTCAAG-3’ 
GFP173-R 5’-GGA CTG GGT GCT CAG GTA GTG G-3’ 
Negative 
control 
siRNA 
Sense 5’-rCrGrUrUrArArUrCrGrCrGrUrArUrArArUrArCrrGrCrGrUrAT-3’ 
Antisense 5’-rCrArGrCrArArUrUrrArGrCrGrArUrArUrUrArUrGrCrGrCrAUrA-3’ 
Human 
siSGLT2 
Sense 5’-rCrCrUrArGrUrCrArUrUrGrCrUrGrCrArUrArUrUrUrCrCTG-3’ 
Antisense 5’-rCrArG rGrArA rArUrA rUrGrC rArGrC rArArU rGrArC rUrArG rGrArU-3’ 
Mouse 
siSglt2 
Sense 5’-rUrGrUrUrCrArGrArArCrCrArArUrArrGrArGrGrCrArCrAGT-3’ 
Antisense 5’-rArCrU rGrUrG rCrCrU rCrUrA rUrUrG rGrUrU rCrUrG rArArC rArUrA-3’ 
Cy3-labeled 
Mouse 
siSglt2 
Cy3-Sense 5’- Cy3-C3-rUrGrUrUrCrArGrArArCrCrArArUrArrGrArGrGrCrArCrAGT-3’ 
Antisense 5’- rArCrUrGrUrGrCrCrUrCrUrArUrUrGrGrUrUrCrUrGrArArCrArUrA-3’ 
Cy3 = cyanine 3 fluorophore 
C3 = spacer 
r = ribose base otherwise deoxyribose base 
 
 
Table 19: Primer/probes for qPCR 
Target Gene name Company Catalog number 
Human SGLT2 SLC5A2 Life Technologies Hs00894642_m1 
Human SGLT1 SLC5A1 Life Technologies Hs01573790_m1 
Human TATA box Binding Protein TBP Life Technologies Hs00427620_m1 
Mouse Sglt2 Slc5a2 Life Technologies Mm00453831_m1 
Mouse Sglt1 Slc5a1 Life Technologies Mm00451203_m1 
Eukaryotic GAPDH GAPDH Life Technologies 4352339E 
Enhanced Green 
Fluorescent Protein 
eGFP Life Technologies Mr04329676 
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Table 20: Antibodies used 
Primary antibodies Supplier 
Catalog 
number 
Dilution used 
Mouse monoclonal anti SGLT2 Abcam ab58298 1:100 – 1:1000 
Rabbit polyclonal anti SGLT1 Abcam ab14686 1:1000 
Rabbit monoclonal GAPDH-HRP conjugate 
Cell 
Signaling 
14C10 1:10000 
Rabbit polyclonal anti SGLT2 (for IHC) Abcam ab85626 
0.9ug/mL or 
1.8ug/mL 
    
Secondary antibodies Supplier Catalog number Dilution used 
Goat anti rabbit-HRP conjugate Santa Cruz sc-2030 1:10000 
Goat anti mouse-HRP conjugate Santa Cruz sc-2005 1:10000 
 
 
Figure 54: Forward and reverse pH titrations of CNC. Samples in water (0.1mg/mL) of pristine or 
functionalized CNC were titrated initially with NaOH (black plots) to fully deprotonate the CNC followed by a 
reverse titration with HCl (red plots).  
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Figure 55: Isolation, Containment and Urine Production (iCUP). A 2L beaker is used to house a mouse with a 
funnel and plastic wrap to collect and pool the urine. Two metal filters are added to prevent contamination form 
feces and the mouse. 
 
 
Figure 56: Mouse tissues stained with a negative control antibody. A panel of murine tissues was stained with 
rabbit IgG only as a negative control for IHC. The brain, liver and testis show diffuse staining indicating nonspecific 
binding of the antibody. While the spleen, lung, intestines and kidney show no staining with the control antibody. 
Cell nuclei were stained with DAPI (blue). Sglt2 protein appears as brown. The scale bars (lower left) represent 
50um. 
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